<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005507.pub2" GROUP_ID="PVD" ID="688405070411442252" MERGED_FROM="" MODIFIED="2013-08-09 08:44:24 +0100" MODIFIED_BY="Marlene Stewart" REVIEW_NO="1071" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2013-08-09 08:44:24 +0100" MODIFIED_BY="Marlene Stewart">
<TITLE MODIFIED="2012-11-01 15:29:26 +0000" MODIFIED_BY="[Empty name]">Cryoplasty for peripheral arterial disease</TITLE>
<CONTACT MODIFIED="2013-08-09 08:44:24 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="A49A1CBD82E26AA2002589C3A469576D" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>McCaslin</LAST_NAME><SUFFIX>MBBS, MRCS, MD</SUFFIX><POSITION>Vascular Registrar</POSITION><EMAIL_1>mccaslin@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Northern Vascular Centre</DEPARTMENT><ORGANISATION>Freeman Hospital</ORGANISATION><CITY>Newcastle upon Tyne</CITY><ZIP>NE7 7DN</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2448434</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-08-09 08:44:24 +0100" MODIFIED_BY="Marlene Stewart"><PERSON ID="A49A1CBD82E26AA2002589C3A469576D" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>McCaslin</LAST_NAME><SUFFIX>MBBS, MRCS, MD</SUFFIX><POSITION>Vascular Registrar</POSITION><EMAIL_1>mccaslin@doctors.org.uk</EMAIL_1><ADDRESS><DEPARTMENT>Northern Vascular Centre</DEPARTMENT><ORGANISATION>Freeman Hospital</ORGANISATION><CITY>Newcastle upon Tyne</CITY><ZIP>NE7 7DN</ZIP><REGION>Tyne &amp; Wear</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2448434</PHONE_1></ADDRESS></PERSON><PERSON ID="58101036010735430743110819104321" ROLE="AUTHOR"><FIRST_NAME>Alina</FIRST_NAME><LAST_NAME>Andras</LAST_NAME><POSITION>Senior Health Services Researcher</POSITION><EMAIL_1>alinaro@hotmail.com</EMAIL_1><EMAIL_2>alina.andras@nuth.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Vascular Surgery</DEPARTMENT><ORGANISATION>Freeman Hospital</ORGANISATION><ADDRESS_1>Newcastle upon Tyne Hospitals NHS Foundation Trust</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE7 7DN</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="15801" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gerard</FIRST_NAME><LAST_NAME>Stansby</LAST_NAME><POSITION>Professor of Vascular Surgery</POSITION><EMAIL_1>Gerard.Stansby@nuth.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Surgery</DEPARTMENT><ORGANISATION>University of Newcastle upon Tyne</ORGANISATION><ADDRESS_1>Framlington Place</ADDRESS_1><CITY>Newcastle upon Tyne</CITY><ZIP>NE24HH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 191 2336161 ext: 26204</PHONE_1><FAX_1>+44 191 2225979</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-04-23 14:20:01 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="26" MONTH="10" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="10" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-06 11:48:37 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-06 11:48:02 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>Search has been re-run, seven new studies have been included, 11 additional studies excluded and two ongoing studies identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-08-06 11:48:37 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="7" YEAR="2013"/>
<DESCRIPTION>
<P>New author has joined the review team, search has been re-run, seven new studies included, 11 additional studies excluded and two ongoing studies identified. Conclusions changed from previous version of the review which contained no included studies.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-12-01 13:29:57 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-12-01 13:29:57 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>New search has been performed. No new studies identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-07-22 11:30:44 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2013-02-27 11:51:13 +0000" MODIFIED_BY="Heather  Maxwell">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2013-02-27 11:51:13 +0000" MODIFIED_BY="Heather  Maxwell">
<SOURCE MODIFIED="2013-02-27 11:51:13 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institue of Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>AA is supported by a programme grant from the NIHR.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-11-02 11:55:26 +0000" MODIFIED_BY="Heather  Maxwell">
<NAME>Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by the Chief Scientist Office.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-11-02 11:55:22 +0000" MODIFIED_BY="[Empty name]">
<NAME>National Institute of Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The PVD Group editorial base is supported by a programme grant from the NIHR.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-08-08 11:54:37 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-08-06 12:07:28 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Cryoplasty for peripheral vascular disease</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-06 12:07:28 +0100" MODIFIED_BY="[Empty name]">
<P>Peripheral arterial disease results from narrowing or blocking of the main arteries to the legs, usually due to atherosclerosis. The resulting reduction of blood flow caused by a blocked or narrowed artery can either cause pain on walking or become so severe that loss of the leg is threatened. Endovascular surgery involves inserting a small balloon through a needle puncture into the affected artery. The balloon is then inflated to stretch the artery open (called percutaneous balloon angioplasty). Unfortunately the artery often narrows again over time, which is called restenosis. Cryoplasty cools the vessel wall at the same time as doing the balloon angioplasty and may reduce thickening of the inner muscular layer of the blood vessel to improve long-term angioplasty results and prevent restenosis. </P>
<P>The benefit of cryoplasty over conventional balloon angioplasty has yet to be definitely established as there are few randomised controlled trials evaluating this method. The technical success rates and rates of unobstructed arteries (primary patency) compared with<I> </I>conventional angioplasty seen in seven trials (478 patients) were inconsistent. Long-term outcomes, in particular, are as yet to be assessed fully. Currently there are insufficient data to support the routine use of cryoplasty over conventional balloon angioplasty in the treatment of peripheral arterial disease.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-08-06 12:03:52 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-08-06 11:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>Percutaneous balloon angioplasty is an endovascular technique for restoring blood flow through an artery that has become narrowed or blocked by atherosclerosis. Narrowing of the artery following angioplasty (restenosis) is the major cause of long-term failure. Cryoplasty offers a different approach to improving long-term angioplasty results. It combines the dilation force of balloon angioplasty with cooling of the vessel wall. This systematic review evaluated cryoplasty in peripheral arterial disease and provides focus for further research in the field. This is an update of a review first published in 2007.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-07-26 08:04:22 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy of, and complications associated with, cryoplasty for maintaining patency in the iliac, femoropopliteal and crural arteries in the short and medium term.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-07-26 08:04:21 +0100" MODIFIED_BY="[Empty name]">
<P>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched October 2012) and CENTRAL (2012, Issue 10). Trial databases were searched for ongoing or unpublished studies. We also searched the reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-08-06 11:54:49 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials in which participants with peripheral arterial disease (PAD) of the lower limbs, or lower limb bypass graft stenoses, were randomised to cryoplasty with or without another procedure versus a procedure without cryoplasty were considered. This included trials where all participants received angioplasty and the randomisation was for cryoplasty versus no cryoplasty and trials where cryoplasty was used as an adjunct to conventional treatment (for example stenting) against a control.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-07-26 09:58:43 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently reviewed, assessed and selected trials, extracted data and assessed risk of bias. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-08-06 12:00:17 +0100" MODIFIED_BY="[Empty name]">
<P>Seven trials (six primary cryoplasty and one adjunctive cryoplasty trial) with a combined total of 478 patients were included in this review. The trials reported patency and restenosis either by participant, lesion or vessel location. Follow-up ranged from 30 days to three years.</P>
<P>Target lesion patency measured at various time points in two primary cryoplasty trials showed no statistically significant difference between the treatment groups. The adjunctive cryoplasty study showed that cryoplasty was associated with improved patency only at six months (OR 5.37, 95% CI 1.09 to 26.49, n = 90).</P>
<P>Restenosis measured per patient (two primary cryoplasty trials) showed no statistically significant difference between the treatments. Restenosis measured by lesion (two primary cryoplasty trials) showed a statistically significant difference only within 24 hours of the procedure (OR 0.08, 95% CI 0.04 to 0.18, n = 192) favouring cryoplasty.</P>
<P>Need for re-intervention was not significantly different in primary cryoplasty trial participants (per participant: OR 0.27, 95% CI 0.05 to 1.52, n = 241, I<SUP>2</SUP> = 89%; per lesion: OR 0.59, 95% CI 0.06 to 5.69, n = 307, I<SUP>2</SUP> = 94%). The adjunctive cryoplasty trial did not report on need for intervention.</P>
<P>Immediate success of procedure (within 24 hours) was not significantly different in primary cryoplasty trial participants (per participant: OR 1.63, 95% CI 0.14 to 19.55, n = 340, I<SUP>2</SUP> = 95%; per lesion: OR 1.81, 95% CI 0.19 to 17.36, n = 397, I<SUP>2</SUP> = 90%). The adjunctive cryoplasty trial reported 100% success.</P>
<P>Limb loss, deaths from all causes and the risk of complications immediately after treatment showed no statistically significant differences between the treatments.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-08-06 12:03:52 +0100" MODIFIED_BY="[Empty name]">
<P>The benefit of cryoplasty over conventional angioplasty cannot be established as the number of randomised controlled trials is small and their quality is not sufficiently high. The technical success and primary patency rates seen in these trials are inconsistent and do not necessarily suggest a future role for cryoplasty in the treatment of PAD, but they cannot be reliably interpreted. Currently there are insufficient data to support the routine use of cryoplasty over conventional balloon angioplasty in the treatment of PAD.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-08-08 11:54:37 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-08-07 14:08:58 +0100" MODIFIED_BY="Heather  Maxwell">
<CONDITION MODIFIED="2013-08-07 14:08:58 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Symptomatic peripheral arterial disease (PAD) occurs in 5% to 7% of the population over the age of 55 years (<LINK REF="REF-Dewhurst-1991" TYPE="REFERENCE">Dewhurst 1991</LINK>; <LINK REF="REF-Fowkes-1991" TYPE="REFERENCE">Fowkes 1991</LINK>) and in up to 29% of at risk people over the age of 50 years (<LINK REF="REF-Hirsch-2001" TYPE="REFERENCE">Hirsch 2001</LINK>). In 25% of the patients over the age of 55 years, the condition will deteriorate and require treatment, and 5% will go on to develop limb-threatening critical limb ischaemia (CLI) (<LINK REF="REF-Dormandy-1991" TYPE="REFERENCE">Dormandy 1991</LINK>). Most patients requiring treatment will be candidates for endovascular intervention as first-line treatment, although the evidence base for this approach is still developing (<LINK REF="REF-London-1995" TYPE="REFERENCE">London 1995</LINK>; <LINK REF="REF-White-2007" TYPE="REFERENCE">White 2007</LINK>).</P>
<P>Percutaneous balloon angioplasty is an endovascular technique for restoring blood flow through an artery that has become narrowed or blocked by atherosclerosis. A small balloon is inserted into the artery and inflated, thus rupturing the atheromatous plaque, stretching the smooth muscle cells within the middle of the vessel wall and widening the arterial lumen. Angioplasty is particularly effective in the iliac vessels, but the technique is also successful for treating femoropopliteal arteries. Five-year patency rates for iliac and femoropopliteal angioplasty are reported as 55% to 60% and 52% respectively (<LINK REF="REF-Adar-1989" TYPE="REFERENCE">Adar 1989</LINK>; <LINK REF="REF-Leu-1999" TYPE="REFERENCE">Leu 1999</LINK>; <LINK REF="REF-Long-1991" TYPE="REFERENCE">Long 1991</LINK>; <LINK REF="REF-Martin-1995" TYPE="REFERENCE">Martin 1995</LINK>; <LINK REF="REF-Murphy-1995" TYPE="REFERENCE">Murphy 1995</LINK>), while newer studies of modern stents suggest a patency rate in the iliac artery of around 80% at five years (<LINK REF="REF-Leville-2006" TYPE="REFERENCE">Leville 2006</LINK>; <LINK REF="REF-Park-2005" TYPE="REFERENCE">Park 2005</LINK>; <LINK REF="REF-Park-2007" TYPE="REFERENCE">Park 2007</LINK>).</P>
<P>A Cochrane review (which included only 98 patients in total) suggested that although angioplasty may be of short-term benefit, this may not be sustained in the long term (<LINK REF="REF-Fowkes-2001" TYPE="REFERENCE">Fowkes 2001</LINK>). Narrowing of the artery following angioplasty (restenosis) is the major cause of long-term failure. Restenosis is caused by three processes, immediate elastic recoil of the vessel, myointimal hyperplasia (enlargement of the inner muscular layer of vessels), and late vascular remodelling (changes in the vessel, produced in response to physical stresses on the vessel wall, which affect the shape and volume of the vessel). The addition of acute thrombosis can lead to complete occlusion (complete blockage) of a restenosed vessel.</P>
<P>Myointimal hyperplasia, that is the unrestricted migration and proliferation of vascular smooth muscle cells into the vessel lumen, leads to narrowing and restriction of blood flow. The stimulus for this cellular migration is unclear and therapeutic approaches are being eagerly sought to regulate this process (<LINK REF="REF-Clowes-1983" TYPE="REFERENCE">Clowes 1983</LINK>; <LINK REF="REF-Dilley-1988" TYPE="REFERENCE">Dilley 1988</LINK>; <LINK REF="REF-Mintz-1996" TYPE="REFERENCE">Mintz 1996</LINK>; <LINK REF="REF-Sottiurai-1983" TYPE="REFERENCE">Sottiurai 1983</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-06-11 13:52:53 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Cryoplasty offers a different approach to improving long-term angioplasty results. It combines the dilation force of balloon angioplasty with cooling of the vessel wall. Cryotherapy is already widely adopted in other fields of medicine as an effective modality. Previous studies have demonstrated a benign histological response in arteries in response to cold thermal energy, with no interruption in conduit function (<LINK REF="REF-Gage-1967" TYPE="REFERENCE">Gage 1967</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-08-07 11:38:59 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Cryoplasty is thought to provoke apoptosis (a form of cell death necessary to make way for new cells) rather than necrosis (the death of cells in a tissue or organ caused by disease of injury) in the arterial smooth muscle cells. Thus it has the theoretical advantage of reduced myointimal hyperplasia in long-term patency (<LINK REF="STD-Fava-2004" TYPE="STUDY">Fava 2004</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-08-07 11:39:20 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Many questions remain regarding the safety and efficacy of cryoplasty for PAD. This systematic review of available trial data aims to evaluate the treatment and provide focus for further research in the field.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-08-07 11:40:49 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the efficacy of, and complications associated with, cryoplasty for maintaining patency in the iliac, femoropopliteal and crural arteries in the short and medium term.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-08-08 11:54:15 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-08-07 11:47:01 +0100" MODIFIED_BY="Heather  Maxwell">
<CRIT_STUDIES MODIFIED="2013-08-07 11:42:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials in which patients with peripheral arterial disease (PAD) of the lower limbs or lower limb bypass graft stenoses were randomised to cryoplasty with or without another procedure versus a procedure without cryoplasty or non-interventional medical treatment. This included trials where all patients received angioplasty and the randomisation was for cryoplasty versus no cryoplasty and trials where cryoplasty was used as an adjunct to conventional treatment (for example stenting) against a control.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-08-07 11:44:10 +0100" MODIFIED_BY="[Empty name]">
<P>Men and women of any age, diagnosed with PAD by an expert clinician through clinical and investigative assessment (ankle-brachial pressure index, duplex, exercise testing, angiography, computerised tomography (CT), angiography or magnetic resonance (MR) angiography), and who required vascular intervention that could be appropriately managed with cryoplasty and were deemed fit to undergo such an intervention. We intended to stratify these patients on a symptomatic basis (for example rest pain, tissue loss, claudication distance) or by the Transatlantic Inter-Society Consensus (TASC) criteria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-08-07 11:45:41 +0100" MODIFIED_BY="Heather  Maxwell">
<P>Trials including any form of therapy that involved the use of cryoplasty for the treatment of PAD were considered for inclusion. We intended to divide trials into subgroups according to the indication for intervention (critical limb ischaemia (CLI), intermittent claudication (IC)); and de novo or repeat procedures. Additional therapies, in particular the adjuvant use of antiplatelet or anticoagulant agents, were assessed.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-08-07 11:47:01 +0100" MODIFIED_BY="Heather  Maxwell">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-08-07 11:46:18 +0100" MODIFIED_BY="Heather  Maxwell">
<P>The following primary outcome measures were considered:</P>
<UL>
<LI>patency, restenosis or occlusion at various time points (e.g. 30 days, three months, six months, 12 months) using imaging studies or haemodynamics;</LI>
<LI>need for re-intervention;</LI>
<LI>limb loss.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-08-07 11:47:01 +0100" MODIFIED_BY="Heather  Maxwell">
<P>The following secondary outcome measures were considered:</P>
<UL>
<LI>immediate success of procedure (within 24 hours);</LI>
<LI>cardiovascular death (i.e. death from any atherogenic cause, cerebrovascular accident, myocardial infarction, aneurysm, etc., including death during surgery for these conditions);</LI>
<LI>death from all causes;</LI>
<LI>complications (e.g. late thrombosis, aneurysm formation, nerve damage, dissection of vessel);</LI>
<LI>ankle-brachial index (ABI);</LI>
<LI>walking distance;</LI>
<LI>maximum walking distance on treadmill;</LI>
<LI>grading of patency on duplex scanning or angiography;</LI>
<LI>time to restenosis;</LI>
<LI>quality of life assessments.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-08-07 11:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>We applied no language restriction on publications or any restrictions regarding publication status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-08-07 11:51:19 +0100" MODIFIED_BY="[Empty name]">
<P>For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched October 2012) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2012, Issue 10), part of <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used, are described in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html">Specialised Register</A> section of the Cochrane Peripheral Vascular Diseases (PVD) Group module in <I>The Cochrane Library</I> (<A HREF="http://www.thecochranelibrary.com">www.thecochranelibrary.com</A>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>The following trial databases were searched by the TSC (September 2012) for details of ongoing and unpublished studies using the terms cryotherapy or cryoplasty:</P>
<P>World Health Organization International Clinical Trials Registry (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>);</P>
<P>ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov/">http://clinicaltrials.gov/</A>);</P>
<P>Current Controlled Trials (<A HREF="http://www.controlled-trials.com/">http://www.controlled-trials.com/</A>).</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-08-07 11:49:45 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of articles and reports retrieved by electronic searches for additional citations. We also contacted the authors for further information when the data were missing or we were unsure whether to include trials in the review.</P>
<P>We contacted the cryoplasty device manufacturers (Boston Scientific, Natick, MA) to obtain any unpublished, missed or forthcoming trial work.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-08-08 11:54:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>We performed one analysis for the trials included in this review.</P>
<STUDY_SELECTION MODIFIED="2013-08-07 11:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>The contact author (JM) and the co-authors (AA, GS) carried out the selection of trials for inclusion in the review. Two authors (JM, AA) independently assessed the methodological quality of each trial, with arbitration in the event of disagreement from the third co-author (GS), using the checklist recommended by the Cochrane PVD Group.</P>
<P>We obtained full versions of articles that potentially met the inclusion criteria based on the title or abstract and assessed these independently against the inclusion criteria. The reason for a study's exclusion is presented in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-08-08 11:53:45 +0100" MODIFIED_BY="[Empty name]">
<P>Data extraction was carried out by the contact author (JM) and one of the co-authors (AA) independently, including information on participants (age and sex distribution, measures of severity of disease such as ABI), interventions and outcomes (as above). Any information absent in the publications was sought directly from the authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-08-07 11:54:19 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (AA, JM) assessed the methodological quality of the studies using the 'Risk of bias' tool from The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed the following domains: selection bias, performance and detection bias, attrition bias, reporting bias and other sources of bias. We allocated a judgement of high risk of bias, low risk of bias, or unclear risk of bias according to the guidelines from <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-08-07 11:54:36 +0100" MODIFIED_BY="[Empty name]">
<P>We used Review Manager 5.2 provided by The Cochrane Collaboration to analyse the data. For dichotomous outcomes, statistical analysis was presented as odds ratio (OR) with 95% confidence interval (CI). We used mean differences (MD) with 95% CIs for continuous outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-08-08 11:54:15 +0100" MODIFIED_BY="[Empty name]">
<P>Participating individuals in the individually randomised trials were the unit of analysis. If data were not available in this unit of analysis, we used lesions as the unit of analysis and we have reported this.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-08-07 11:55:22 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the principal authors of included studies, when necessary, to clarify data and to provide missing information.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-07-11 14:48:28 +0100" MODIFIED_BY="[Empty name]">
<P>We based all analyses on the intention-to-treat data from individual trials. We assessed trial heterogeneity using the I<SUP>2</SUP> statistic. Where heterogeneity was identified (I<SUP>2 </SUP>&gt; 50%), we investigate the reason for heterogeneity. If no apparent reason was found, we conducted a random-effects model meta-analysis. In the absence of heterogeneity, we used a fixed-effect model.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-08-07 11:56:13 +0100" MODIFIED_BY="[Empty name]">
<P>We planned to use asymmetry in funnel plots to assess reporting bias. However, due to the small number of included trials, this was not performed as the power of analysis would have been too low to distinguish chance from real asymmetry.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-07-09 14:46:39 +0100" MODIFIED_BY="[Empty name]">
<P>We used a random-effects model where clinical and statistical heterogeneity existed (I<SUP>2 </SUP>&gt; 50%). We used a fixed-effect model in the absence of heterogeneity.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-08-07 11:57:07 +0100" MODIFIED_BY="[Empty name]">
<P>It was intended to perform subgroup analyses to include use of adjuvant therapy (including stenting), vascular territory, indication for intervention, type and length of lesion, initial presentation (TASC criteria and symptoms), and presence of diabetes. Patients with vessels requiring re-intervention (with stratification for time from intervention to re-intervention) were also intended to be analysed as a subgroup. However, due to the restricted number of small trials, this was only done in the case of adjuvant use of cryoplasty in stenting of the femoropopliteal segment.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-03-13 10:17:38 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to perform sensitivity analyses based on the risk of bias if there were studies with high risk of bias (that is, with high risk methods of allocation concealment and random sequence generation) included in the analyses.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-08-08 11:54:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-08-08 11:49:58 +0100" MODIFIED_BY="[Empty name]">
<P>For a detailed description of studies see: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2013-08-07 12:00:10 +0100" MODIFIED_BY="[Empty name]">
<P>For this update seven randomised controlled trials pertaining to cryoplasty in the treatment of PAD were identified following screening of the CENTRAL and PVD Specialised Register search results. A further 11 studies were excluded and two ongoing studies were identified. Case series examining the short- and medium-term results of cryoplasty were excluded (see<I> </I>table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-08-08 11:49:58 +0100" MODIFIED_BY="[Empty name]">
<P>See the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>In total seven trials were included in this review (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</P>
<P>The breakdown of trials according to the countries in which they were performed was as follows:</P>
<UL>
<LI>China: <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>;</LI>
<LI>Germany: <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>;</LI>
<LI>Greece: <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>;</LI>
<LI>Italy: <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>;</LI>
<LI>Spain: <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>;</LI>
<LI>USA: <LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>, <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>.</LI>
</UL>
<P>A total of 478 patients were recruited into the trials. The number of participants in each trial ranged from 25 (<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) to 155 (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>). These trials considered cryoplasty versus angioplasty for iliac and infra-inguinal arterial disease (<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>), femoropopliteal arterial disease (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) and popliteal arterial disease (<LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>). One trial examined the use of cryoplasty in the treatment of in-stent restenosis after superficial femoral artery stenting with nitinol self-expanding stents (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>). Three of the trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) included only patients with diabetes, three studies included diabetic and non-diabetic patients (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>) and one study did not specify if the patients had any pre-existing conditions (<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</P>
<P>The seven trials included were:</P>
<UL>
<LI>primary cryoplasty trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>);</LI>
<LI>an adjunctive cryoplasty trial (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>).</LI>
</UL>
<P>Primary cryoplasty trials are defined as trials comparing cryoplasty only with a procedure without cryoplasty. Adjunctive cryoplasty trials are defined as trials comparing cryoplasty used as an adjunct to conventional treatment (for example stenting) with a procedure without cryoplasty.</P>
<P>Mixed units of analysis were used by the seven included trials and a list of these units is included as follows:</P>
<UL>
<LI>per patient (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>);</LI>
<LI>per lesion (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>);</LI>
<LI>per site (vessels location SFA and PA) (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>).</LI>
</UL>
<P>Two trials also used as additional units of analysis: limbs (<LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) and vessels (<LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>).</P>
<P>The investigated blood vessels were as follows:</P>
<UL>
<LI>iliac and infrainguinal arteries (<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>);</LI>
<LI>femoropopliteal arteries (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>);</LI>
<LI>popliteal artery (<LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>).</LI>
</UL>
<P>Power calculations were not reported in any of the trials. Intention-to-treat analysis was performed in all seven trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</P>
<P>The length of the follow-up varied between trials:</P>
<UL>
<LI>30 days (<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>);</LI>
<LI>6 months (<LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>);</LI>
<LI>12 months (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>);</LI>
<LI>15 months (<LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>);</LI>
<LI>up to 3 years (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>).</LI>
</UL>
<P>In terms of primary outcome events, five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>) reported patency, restenosis or occlusion at various time points. Need for re-intervention was reported in four trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>), while limb loss was reported in three trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>).</P>
<P>In terms of secondary outcome events, the following information was reported:</P>
<UL>
<LI>immediate success of the procedures was reported in all trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>);</LI>
<LI>death from all causes was reported for various time points in five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>);</LI>
<LI>complications occurring immediately post-treatment were reported in five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>);</LI>
<LI>ankle-brachial pressure was reported at different time points in five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</LI>
</UL>
<P>Sources of funding were declared in two trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-08-07 12:12:14 +0100" MODIFIED_BY="[Empty name]">
<P>There were 16 studies excluded. For this update 11 studies (<LINK REF="STD-Bakken-2008" TYPE="STUDY">Bakken 2008</LINK>; <LINK REF="STD-Banerjee-2009" TYPE="STUDY">Banerjee 2009</LINK>; <LINK REF="STD-Basco-2012" TYPE="STUDY">Basco 2012</LINK>; <LINK REF="STD-Bosiers-2010" TYPE="STUDY">Bosiers 2010</LINK>; <LINK REF="STD-FIX_x002d_IT-Retro" TYPE="STUDY">FIX-IT Retro</LINK>; <LINK REF="STD-Gisbertz-2009" TYPE="STUDY">Gisbertz 2009</LINK>; <LINK REF="STD-Gonzalo-2010" TYPE="STUDY">Gonzalo 2010</LINK>; <LINK REF="STD-Korteweg-2009" TYPE="STUDY">Korteweg 2009</LINK>; <LINK REF="STD-Schmieder-2010" TYPE="STUDY">Schmieder 2010</LINK>; <LINK REF="STD-Shin-2010" TYPE="STUDY">Shin 2010</LINK>; <LINK REF="STD-Silva-2011" TYPE="STUDY">Silva 2011</LINK>) were excluded in addition to those excluded in the previous version (<LINK REF="STD-Das-2009" TYPE="STUDY">Das 2009</LINK>; <LINK REF="STD-Fava-2004" TYPE="STUDY">Fava 2004</LINK>; <LINK REF="STD-Karthik-2007" TYPE="STUDY">Karthik 2007</LINK>; <LINK REF="STD-Laird-2006" TYPE="STUDY">Laird 2006</LINK>; <LINK REF="STD-Samson-2008" TYPE="STUDY">Samson 2008</LINK>). Studies were excluded for the following reasons:</P>
<UL>
<LI>retrospective analysis (<LINK REF="STD-Bakken-2008" TYPE="STUDY">Bakken 2008</LINK>; <LINK REF="STD-Basco-2012" TYPE="STUDY">Basco 2012</LINK>; <LINK REF="STD-FIX_x002d_IT-Retro" TYPE="STUDY">FIX-IT Retro</LINK>; <LINK REF="STD-Schmieder-2010" TYPE="STUDY">Schmieder 2010</LINK>; <LINK REF="STD-Shin-2010" TYPE="STUDY">Shin 2010</LINK>; <LINK REF="STD-Silva-2011" TYPE="STUDY">Silva 2011</LINK>);</LI>
<LI>case series (<LINK REF="STD-Fava-2004" TYPE="STUDY">Fava 2004</LINK>; <LINK REF="STD-Gisbertz-2009" TYPE="STUDY">Gisbertz 2009</LINK>; <LINK REF="STD-Gonzalo-2010" TYPE="STUDY">Gonzalo 2010</LINK>; <LINK REF="STD-Karthik-2007" TYPE="STUDY">Karthik 2007</LINK>; <LINK REF="STD-Samson-2008" TYPE="STUDY">Samson 2008</LINK>);</LI>
<LI>non-randomised controlled trials (<LINK REF="STD-Banerjee-2009" TYPE="STUDY">Banerjee 2009</LINK>; <LINK REF="STD-Das-2009" TYPE="STUDY">Das 2009</LINK>; <LINK REF="STD-Laird-2006" TYPE="STUDY">Laird 2006</LINK>);</LI>
<LI>multicentre registry (<LINK REF="STD-Bosiers-2010" TYPE="STUDY">Bosiers 2010</LINK>);</LI>
<LI>pilot study without control arm (<LINK REF="STD-Korteweg-2009" TYPE="STUDY">Korteweg 2009</LINK>).</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-08-07 12:19:03 +0100" MODIFIED_BY="[Empty name]">
<P>See also the 'Risk of bias' tables for the included studies and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2013-08-07 12:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>In four trials (<LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) the method of treatment allocation was described as 'random', using generated random number or sealed envelopes containing the treatment, with a low perceived risk of bias. In one trial (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>) the allocation was not described. In two trials the patients were randomised according to the operator's preference (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>) or during the procedure (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) with a high perceived risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-08-07 12:15:21 +0100" MODIFIED_BY="[Empty name]">
<P>Only in one trial (<LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>) was the blinding assured, with a low risk of bias. The blinding of trial personnel to treatment allocation was not clear in three trials (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>). In two trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>) personnel were not blinded and in one trial (<LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) the envelopes were opened only after lesions were successfully crossed, with high risk of bias.</P>
<P>In one trial (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>) the detection bias was low as the outcomes were assessed independently. The other six studies (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) did not provide information and were perceived as having an unclear risk of bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-08-07 12:18:11 +0100" MODIFIED_BY="[Empty name]">
<P>All trials conducted intention-to-treat analyses, and continued follow-up reporting of most of the patients. The risk of bias was high for two trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>) as not all patients reached the expected follow-up and partial data were reported.</P>
<P>The risk of bias was low for five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) as all the outcome data were accounted for.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-03-13 10:23:47 +0000" MODIFIED_BY="[Empty name]">
<P>Five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) were free of reporting bias. However, the risk of bias was high for the other two trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) because not all outcomes were reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-08-07 12:19:03 +0100" MODIFIED_BY="[Empty name]">
<P>Five trials had a low risk of bias (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>), while two trials were at high risk of other sources of bias because the patients were randomised after stenting (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) or by operator preference (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-08-08 11:54:37 +0100" MODIFIED_BY="[Empty name]">
<P>Seven trials that fulfilled the inclusion criteria were included in the review. The data were reported as per patient or per lesion in six trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) and as per site in one trial (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>).</P>
<P>Out of the 478 patients included in the seven trials, 295 were diabetics. Three trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) included only diabetics, while three other trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>) included both diabetics and non-diabetics but did not analyse the outcomes based on patient groups. One trial did not specify whether any of the included patients were diabetic (<LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>).</P>
<P>The data were presented separately for six primary cryoplasty trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>) and for one adjunctive cryoplasty trial (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Patency, restenosis, occlusion at various time points</HEADING>
<P>One primary cryoplasty trial provided per site (vessels location superficial femoral artery (SFA) and popliteal artery (PA)) data (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>) with 29 sites in the cryoplasty group and 31 sites in the conventional angioplasty group. At six months, the cryoplasty group had 10 stenoses and 18 patent sites, while the conventional angioplasty group had three stenosis and 28 patent sites, with a statistically significant reduction in restenosis rate (P = 0.02) in the conventional angioplasty group. At 12 months the study authors reported four occlusions, 15 stenoses and eight patent sites in the cryoplasty group, while in the conventional angioplasty group they reported one occlusion, 14 stenoses and 15 patent sites, with no significant difference in the degree of restenosis (P = 0.122).</P>
<P>Binary restenosis was reported by one primary cryoplasty trial (<LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) and one adjunctive cryoplasty trial (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>). At 12 months, binary restenosis occurred in 55.8% of the conventional balloon dilation group and 29.3% of the cryoplasty group (OR 0.36, 95% CI 0.15 to 0.89, n = 74) (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>). In-lesion binary restenosis was significantly higher in the cryoplasty group at 12, 24 and 36 months (OR 1.3, 95% CI 0.6 to 2.6, n = 50) (<LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Per patient data</HEADING>
<P>Two primary cryoplasty trials provided per patient data for target lesion patency (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>). There was no statistically significant difference in patency after six months between patients treated with cryoplasty versus conventional angioplasty for PA occlusive disease (OR 0.62, 95% CI 0.36 to 1.07, n = 241, I<SUP>2</SUP> = 0%). These trials also reported patency per patient at three and nine months (<LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>) and 12, 24 and 36 months (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>), but none of the results showed a statistically significant difference in patency (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Restenosis was reported by two primary cryoplasty trials either within 24 hours of the procedure (<LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>) or at six months follow-up (<LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>), but there was no statistically significant difference between the treatments (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Per lesion data</HEADING>
<P>Patency data per lesion were extracted from one study which examined cryoplasty after SFA stenting (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) at two monthly intervals up to one year. Only at six months, cryoplasty was associated with improved patency at a statistically significant level (OR 5.37, 95% CI 1.09 to 26.49, n = 90). The trend was similar for the other intervals, but they were not statistically significant. However, these limited significant results should be interpreted in the context of randomisation occurring during the procedure, and the resulting high risk of bias of this method (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>Restenosis was reported by two primary cryoplasty trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>). Within 24 hours of the procedure, a statistically significant result (OR 0.08, 95% CI 0.04 to 0.18, n = 192) favoured cryoplasty (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>), although at six months the results were not statistically significant (<LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>). Again, this result was subject to the bias of operator randomisation during the procedure in the trial by <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>, which could have a significant effect on the immediate patency shown (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Need for re-intervention</HEADING>
<P>Per patient data were provided by two primary cryoplasty trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>). There was no statistically significant difference in the need for re-intervention between patients treated with cryoplasty versus conventional angioplasty for PA occlusive disease (OR 0.27, 95% CI 0.05 to 1.52, n = 241, I<SUP>2</SUP> = 89%), with a trend for patients treated by cryoplasty to be at lower risk for re-intervention (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>Per lesion data were provided by three primary cryoplasty trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>). There was no statistically significant difference in the need for re-intervention between patients treated with cryoplasty versus angioplasty for treatment of atherosclerotic lesions in the SFA and PA (OR 0.59, 95% CI 0.06 to 5.69, n = 307, I<SUP>2</SUP> = 94%), with patients treated by cryoplasty at lower risk of re-intervention (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>The adjunctive cryoplasty trial (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) did not report on need for intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Limb loss</HEADING>
<P>There was no statistically significant effect of cryoplasty on limb loss compared with conventional balloon angioplasty in the three trials (adjunctive cryoplasty: <LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; primary cryoplasty: <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) that reported this outcome in patients treated for stenosis or occlusion of the SFA and PA at six, 12 and 24 months, or three years. There was no limb loss at six months (<LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>) or 12 months (<LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) in primary cryoplasty trials (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) or at 12 months in the adjunctive cryoplasty trial (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Immediate success of procedures</HEADING>
<P>Per patient data were provided by four trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>). The combination of data from the three primary cryoplasty trials indicated no statistically significant difference in the immediate success of cryoplasty compared with conventional angioplasty (OR 1.63, 95% CI 0.14 to 19.55, n = 266, I<SUP>2</SUP> = 95%) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), while the adjunctive cryoplasty trial reported 100% success (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>).</P>
<P>Per lesion data were provided by four trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>). The combination of data from the three primary cryoplasty trials indicated no statistically significant difference between procedures (OR 1.81, 95% CI 0.19 to 17.36, n = 307, I<SUP>2</SUP> = 90%) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>), while the adjunctive cryoplasty trial reported 100% success (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
<P>One study reported success rate by site (vessels location: SFA and PA), with technical success achieved in 25/29 sites in the cryoplasty group and 28/31 sites in the angioplasty group (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cardiovascular death</HEADING>
<P>The adjunctive cryoplasty trial (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>) reported three cases of sudden cardiac death but the trialists did not specify in which treatment group these deaths occurred. The primary cryoplasty studies did not report on cardiovascular deaths.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Death from all causes</HEADING>
<P>Death from all causes was reported at different intervals by five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>). No deaths occurred by 30 days or three months follow-up (<LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>). Deaths were reported by four primary cryoplasty trials at six (three trials, n = 245), 12 (three trials, n = 327) and 24 (two trials, n = 205) months, and at three years (two trials, n = 205), and showed no significant difference between cryoplasty and angioplasty (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). Similar results were obtained for the adjunctive cryoplasty trial (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Complications</HEADING>
<P>Complications that occurred immediately after treatment were reported by five trials (<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>). Combining data from the primary cryoplasty trials indicated no statistically significant difference in complication rates for cryoplasty versus conventional angioplasty (OR 2.26, 95% CI 0.70 to 7.37, n = 306, I<SUP>2</SUP> = 0%) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). Similar results were obtained for the adjunctive cryoplasty trial (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ankle-brachial index (ABI)</HEADING>
<P>ABI was reported by five trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Shammas-2012" TYPE="STUDY">Shammas 2012</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>). In one of these (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>) ABI was measured immediately after treatment only. Two trials (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>) reported ABI within 24 hours of the procedures with no statistically significant difference in ABI rates for cryoplasty versus conventional angioplasty (MD -0.05, 95% CI -0.12 to 0.03, n = 241, I<SUP>2</SUP> = 0%). In the other three primary cryoplasty trials, there was a statistically significant difference in ABI between the cryoplasty and angioplasty groups only at three months (MD 0.13, 95% CI 0.02 to 0.24, n = 86) favouring angioplasty (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). The adjunctive cryoplasty trial at 12 months also favoured angioplasty (MD 0.12, 95% CI 0.00 to 0.24, n = 90) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other secondary outcomes</HEADING>
<P>None of the included trials reported any of the other secondary outcomes of this review, including walking distance, maximum walking distance on a treadmill, grading of patency on duplex scanning or angiography, time to restenosis or quality of life assessment.</P>
<P>
<LINK REF="STD-Banerjee-2012" TYPE="STUDY">Banerjee 2012</LINK> reported baseline and follow-up Rutherford stages and walking impairment questionnaires. Mean walking impairment scores were similar after 12 months follow-up (P = 0.53) but were higher compared to baseline in both the cryoplasty (P = 0.005) and the conventional balloon (P = 0.002) groups. Similarly, there were no significant differences between the Rutherford stages at baseline, six months and 12 months follow-up (no P values provided) but the mean Rutherford stage decreased significantly (P &lt; 0.0001) for each treatment arm between baseline and six months and between baseline and 12 months follow-up.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-08-08 11:49:24 +0100" MODIFIED_BY="Heather  Maxwell">
<SUMMARY_OF_RESULTS MODIFIED="2013-08-07 14:12:41 +0100" MODIFIED_BY="[Empty name]">
<P>Two primary cryoplasty trials provided data for target lesion patency at various time points showing no statistically significant difference in patency. The adjunctive cryoplasty study showed that only at six months cryoplasty was associated with improved patency at a statistically significant level (OR 5.37, 95% CI 1.09 to 26.49, n = 90). The trend was similar for the other intervals but these were not statistically significant. Per patient restenosis (two primary cryoplasty trials), either within 24 hours of the procedure or at six-month follow-up, showed no statistically significant difference between the treatments. Per lesion restenosis (two primary cryoplasty trials) showed a statistically significant difference within 24 hours of the procedure (OR 0.08, 95% CI 0.04 to 0.18, n = 192) favouring cryoplasty; at six months the results were not statistically significant.</P>
<P>The need for re-intervention was not significantly different in primary cryoplasty trial participants (per patient: OR 0.27, 95% CI 0.05 to 1.52, n = 241, I<SUP>2</SUP> = 89%; per lesion: OR 0.59, 95% CI 0.06 to 5.69, n = 307, I<SUP>2</SUP> = 94%). The adjunctive cryoplasty trial did not report on need for intervention.</P>
<P>Limb loss was reported at four intervals by three different trials but showed no statistically significant difference at any interval. Immediate success of the procedure (within 24 hours) was not significantly different in patients treated by cryoplasty (OR 1.63, 95% CI 0.14 to 19.55, n = 340, I<SUP>2</SUP> = 95%), with similar results for success of the procedures in lesions (OR 1.81, 95% CI 0.19 to 17.36, n = 397, I<SUP>2</SUP> = 90%). The adjunctive cryoplasty trial reported 100% success.</P>
<P>Deaths from all causes were reported by four primary cryoplasty trials and showed no statistically significant difference between cryoplasty and angioplasty. Similar results were obtained for the adjunctive cryoplasty trial. The risk of complications immediately after treatment was reported by four primary cryoplasty trials and showed no statistically significant difference (OR 2.26, 95% CI 0.70 to 7.37, n = 306, I<SUP>2</SUP> = 0%). Similar results were obtained for the adjunctive cryoplasty trial.</P>
<P>Four primary cryoplasty trials reported no difference in ABI except for one trial at the three-month interval showing a statistically significant difference in ABI (MD 0.13, 95% CI 0.02 to 0.24, n = 86) favouring angioplasty. The adjunctive cryoplasty trial at 12 months also favoured angioplasty (MD 0.12, 95% CI 0.00 to 0.24, n = 90).</P>
<P>The seven studies included in this review were grouped by units of analysis (per patient or per lesion) and were further grouped by primary or adjunctive cryoplasty trials. The grouping meant that many subgroup analyses included only one trial with either unit of analysis at any time point. Therefore, there is little evidence to support that the outcomes differ between primary or adjunctive cryoplasty trials.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-08-07 13:53:04 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, the data are not sufficient to make robust practice recommendations for cryoplasty. As three studies included only diabetic patients and as over 60% (295/478) of the included patients were diabetics, and because of the variety of outcome measures, the data potentially do not represent a complete picture for using cryoplasty in the treatment of peripheral arterial disease (PAD).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-08-07 13:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>The review included only direct comparisons of the two procedures. The effect estimates for some of the primary outcome patency, restenosis, occlusion at various time points, and limb loss produced narrow 95% confidence intervals; together with the absence of heterogeneity between trials these suggest that the findings are robust. However, for the outcomes 'need for re-intervention' and 'immediate success of procedures', where the heterogeneity was more than 50%, the findings should be interpreted with caution.</P>
<P>Only four studies specified the method of sequence generation, two studies did not specify the method of sequence generation, and one study did not provide sufficient information and therefore was classed as at unclear risk of selection bias. Allocation concealment was appropriately presented in four studies, in two studies the concealment was not considered, and one study did not include sufficient information. The risk of performance bias was low for one study, unclear for three studies because of insufficient information, and high risk for three studies because the study personnel were not blinded or the patients were randomised only after lesions were successfully crossed. Only one of the studies was at low risk of detection bias and the remaining six studies did not include sufficient information and were assessed to be at unclear risk of bias. Five studies presented all expected outcomes and were at low risk of attrition bias and two studies were at high risk because not all expected outcomes were reported. Five studies were deemed to be at low risk of other bias while two studies were at high risk of other bias because the operators allocated the treatments.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-08-07 14:01:05 +0100" MODIFIED_BY="[Empty name]">
<P>The methods used to conduct the review are described in detail in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Particular strengths are the independent application of the review eligibility criteria, independent data extraction and assessment of the risk of bias. The search strategies were designed and run by the Cochrane PVD group Trials Search Co-ordinator. Two authors (AA, JM) independently selected the included studies and extracted the data. All relevant studies were identified and included in this review. Further data and information were obtained in order to be included in specific outcomes of this review. Studies used patient, lesion, or both, as the unit of analysis. The results were separated by patient or lesion as the unit of analysis and the interpretation of the results may be affected as some patients had more than one lesion and subsequently received more than one treatment.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-08-08 11:49:24 +0100" MODIFIED_BY="[Empty name]">
<P>No other published systematic reviews of randomised controlled trials (RCTs) in which patients with PAD of the lower limbs or lower limb bypass graft stenoses were randomised to cryoplasty with or without another procedure versus a procedure without cryoplasty or non-interventional medical treatment were identified. Other non-RCT evidence has been reported in the form of registries, case series and retrospective cohorts and reviews. </P>
<P>The effects of freeze injury on arterial smooth muscle has been studied in animal (<LINK REF="REF-Gage-1967" TYPE="REFERENCE">Gage 1967</LINK>) and human models (<LINK REF="REF-Grassl-2005" TYPE="REFERENCE">Grassl 2005</LINK>). The first in vivo human experience was reported by Fava et al in 2004 (<LINK REF="STD-Fava-2004" TYPE="STUDY">Fava 2004</LINK>). Cryoplasty has received mixed support in the last five years. A number of reports (<LINK REF="STD-Das-2009" TYPE="STUDY">Das 2009</LINK>; <LINK REF="STD-Fava-2004" TYPE="STUDY">Fava 2004</LINK>; <LINK REF="STD-Laird-2006" TYPE="STUDY">Laird 2006</LINK>) supported the use of cryoplasty, several reports (<LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Karthik-2007" TYPE="STUDY">Karthik 2007</LINK>; <LINK REF="STD-Korteweg-2009" TYPE="STUDY">Korteweg 2009</LINK>; <LINK REF="STD-Samson-2008" TYPE="STUDY">Samson 2008</LINK>; <LINK REF="STD-Shin-2010" TYPE="STUDY">Shin 2010</LINK>) did not support the use of cryoplasty, while one retrospective study (<LINK REF="STD-Schmieder-2010" TYPE="STUDY">Schmieder 2010</LINK>) found cryoplasty an expensive tool with marginal clinical benefit.</P>
<P>One limitation of cryoplasty relates to the cost effectiveness, especially if cryoplasty adds procedural costs without improved clinical outcomes. The cost of cryoplasty was higher than stenting and up to three times more expensive than conventional balloon angioplasty according to the included study by <LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>. It is considered to be close to USD 2000 (<LINK REF="STD-Samson-2008" TYPE="STUDY">Samson 2008</LINK>; <LINK REF="STD-Schmieder-2010" TYPE="STUDY">Schmieder 2010</LINK>).</P>
<P>A comment on the COBRA trial (<LINK REF="REF-Prasad-2012" TYPE="REFERENCE">Prasad 2012</LINK>) highlighted the need for performing RCTs by comparing 16 trials, out of which four RCTs (<LINK REF="STD-Diaz-2011" TYPE="STUDY">Diaz 2011</LINK>; <LINK REF="STD-Fossaceca-2011" TYPE="STUDY">Fossaceca 2011</LINK>; <LINK REF="STD-Jahnke-2010" TYPE="STUDY">Jahnke 2010</LINK>; <LINK REF="STD-Spiliopoulos-2010" TYPE="STUDY">Spiliopoulos 2010</LINK>) were included in this review. Even though the COBRA study showed that cryoplasty is a good alternative for angioplasty, its findings were limited by the small number of patients and by co-morbidities as all included patients were diabetics. </P>
<P>Cryoplasty reviews underlined that the use of cryoplasty is hardly justified in the management of PVD as it brings no gain for patency (<LINK REF="REF-Karthik-2007a" TYPE="REFERENCE">Karthik 2007a</LINK>) and the advantages of cryoplasty over balloon angioplasty are considered minimal (<LINK REF="REF-Kessel-2008" TYPE="REFERENCE">Kessel 2008</LINK>; <LINK REF="REF-Wildgruber-2008" TYPE="REFERENCE">Wildgruber 2008</LINK>). While cryoplasty can be used for treating SFA, PA and infra-popliteal lesions, the long-term outcomes are unknown. There is limited evidence to suggest that cryoplasty may not yield the same results in patients with restenosis. Larger RCTs with clearly defined outcomes and time points are required to compare this treatment against other more established practice before it can be widely recommended.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-08-07 14:14:29 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-08-07 14:13:52 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>The benefit of cryoplasty over conventional angioplasty cannot be established as the number of randomised controlled trials is small and their quality is not sufficiently high. The technical success and primary patency rates seen in these trials are inconsistent and do not necessarily suggest a future role for cryoplasty in the treatment of PAD, but cannot be reliably interpreted. Currently there are insufficient data to support the routine use of cryoplasty over conventional balloon angioplasty in the treatment of PAD.</LI>
</UL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-08-07 14:14:29 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Clarification of the role of cryoplasty requires further well designed randomised controlled trials. These trials would need to be adequately powered across a variety of potentially important patient subgroups, such as diabetic and non-diabetic (including with and without stenting), and arterial territories to allow proper evaluation of this method.</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-08-07 03:23:15 +0100" MODIFIED_BY="Heather  Maxwell">
<P>The authors would like to thank the personnel from the Cochrane Peripheral Vascular Disease Review (PVD) Group, especially Marlene Stewart and Karen Welch for their invaluable support and advice.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-08-07 03:25:28 +0100" MODIFIED_BY="Heather  Maxwell">
<P>JM reports: I received travel, course fees, accommodation and meals from Medtronic as part of the Medtronic University program. This is an educational program, and includes registration and attendance at the European Vascular Course 2012. No financial remuneration was received by myself, other than costs of travel, accommodation, course fees and meals. I received sponsorship from Medtronic to attend the Vascular Society annual meeting 2012 in the form of registration fees and accomodation costs. I am a co-founder of UKETS, a not-for-profit trainee initiative which receives funding through sponsorship from endovascular technology and simulation companies (major funding from Medtronic and Mentice). The majority of this sponsorship is non-financial (that is the companies supply trainers on the courses or allow use of their simulators), although some direct financial input is received from Medtronic and Mentice and is used to run events. No profit is derived from this initiative.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-07-12 08:25:26 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Conceiving the review: GS</LI>
<LI>Designing the review: GS, JM</LI>
<LI>Co-ordinating the review: AA</LI>
<LI>Designing electronic search strategy: Cochrane PVD Group editorial base</LI>
<LI>Screening search results: AA, JM</LI>
<LI>Obtaining copies of trials: AA, JM</LI>
<LI>Appraising quality of papers: AA, JM</LI>
<LI>Abstracting data from papers: AA, JM</LI>
<LI>Data management for the review: AA</LI>
<LI>Entering data into RevMan: AA</LI>
<LI>Analysis of data: AA</LI>
<LI>Interpretation of data: all authors</LI>
<LI>Writing the review: AA, JM, GS</LI>
<LI>Draft the final review: all authors</LI>
<LI>Guarantor for the review: GS</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-08-08 11:49:27 +0100" MODIFIED_BY="[Empty name]">
<P>The assessment of the methodological quality of the included studies was updated according to the updated recommended 'Risk of bias' tool of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-12-03 14:37:47 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-08-08 11:51:23 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-08-08 11:51:23 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-08-08 11:51:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Banerjee-2012" MODIFIED="2013-07-12 08:10:39 +0100" MODIFIED_BY="[Empty name]" NAME="Banerjee 2012" YEAR="2011">
<REFERENCE MODIFIED="2013-07-12 08:10:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Banerjee S, Das TS, Abu-Fadel MS, Dippel EJ, Shammas NW, Tran DL, et al</AU>
<TI>Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: The COBRA Trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2012</YR>
<VL>60</VL>
<NO>15</NO>
<PG>1352-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-23 14:21:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Banerjee S</AU>
<TI>COBRA Trial: Cryoplasty or conventional balloon post-dilation of nitinol stents for revascularisation of peripheral arterial segments (http://www.tctmd.com/d.aspx?id=108821&amp;ext=.pdf)</TI>
<SO>TCT 2011: Transcatheter Cardiovascular Therapeutics 23rd Annual Scientific Symposium</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-2011" MODIFIED="2013-03-07 07:47:21 +0000" MODIFIED_BY="[Empty name]" NAME="Diaz 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-03-07 07:47:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diaz ML, Urtasun F, Barberena J, Aranzadi C, Guillen-Grima F, Bilbao JI</AU>
<TI>Cryoplasty versus conventional angioplasty in femoropopliteal arterial recanalization: 3-year analysis of reintervention-free survival by treatment received</TI>
<SO>Cardiovascular and Interventional Radiology</SO>
<YR>2011</YR>
<VL>34</VL>
<NO>5</NO>
<PG>911-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fossaceca-2011" MODIFIED="2013-08-08 11:51:23 +0100" MODIFIED_BY="[Empty name]" NAME="Fossaceca 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-08-08 11:51:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fossaceca R, Guzzardi G, Di Terlizzi M, Divenuto I, Malatesta E, Cerini P, et al</AU>
<TI>Comparison of cryoplasty and conventional angioplasty for treating stenotic-occlusive lesions of the femoropopliteal arteries in diabetic patients: immediate, mid-term and long-term results</TI>
<TO>Confronto tra crioplastica ed angioplastica convenzionale nel trattamento delle lesioni steno-ostruttive del tratto femoro-popliteo in pazienti diabetici: risultati immediati e a medio e lungo termine</TO>
<SO>La Radiologia Medica</SO>
<YR>2012</YR>
<VL>117</VL>
<NO>7</NO>
<PG>1176-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jahnke-2010" MODIFIED="2013-08-07 03:30:12 +0100" MODIFIED_BY="[Empty name]" NAME="Jahnke 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-08-07 03:30:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jahnke T, Jamili A, Charalambous N, Huemme T, Trentmann J, Mueller-Huelsbeck S, et al</AU>
<TI>Mid-term results of the COLD study, a prospective, randomized single-center trial to compare cryoplasty versus "Plain old Balloon Angioplasty" (POBA) in the popliteal artery</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2009</YR>
<VL>20 Suppl</VL>
<PG>S89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-04-11 10:54:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jahnke T, Mueller-Huelsbeck S, Charalambous N, Trentmann J, Jamili A, Huemme TH, et al</AU>
<TI>Prospective, randomized single-center trial to compare cryoplasty versus conventional angioplasty in the popliteal artery: midterm results of the COLD study</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>2</NO>
<PG>186-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shammas-2012" MODIFIED="2013-03-06 09:31:28 +0000" MODIFIED_BY="[Empty name]" NAME="Shammas 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-03-06 09:31:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shammas NW, Coiner D, Shammas G, Christensen L, Jerin M</AU>
<TI>Percutaneous lower extremity arterial interventions using primary balloon angioplasty versus cryoplasty: a randomized pilot trial</TI>
<SO>Cardiovascular Revascularization Medicine</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>3</NO>
<PG>172-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spiliopoulos-2010" MODIFIED="2013-03-07 07:47:42 +0000" MODIFIED_BY="[Empty name]" NAME="Spiliopoulos 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-07 07:47:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spiliopoulos S, Katsanos K, Karnabatidis D, Diamantopoulos A, Kagadis GC, Christeas N, et al</AU>
<TI>Cryoplasty versus conventional balloon angioplasty of the femoropopliteal artery in diabetic patients: long-term results from a prospective randomized single-center controlled trial</TI>
<SO>Cardiovascular and Interventional Radiology</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>5</NO>
<PG>929-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2011" MODIFIED="2013-07-12 08:02:54 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-07-12 08:02:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang X, Zhang B</AU>
<TI>The clinical application of cryoplasty for lower extremity arterial occlusive disease</TI>
<SO>Chinese Journal of Radiology</SO>
<YR>2011</YR>
<VL>45</VL>
<NO>9</NO>
<PG>863-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-08-07 03:35:15 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bakken-2008" MODIFIED="2013-04-11 10:56:10 +0100" MODIFIED_BY="[Empty name]" NAME="Bakken 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-04-11 10:56:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bakken AM, Saad WE, Davies MG</AU>
<TI>Cryoballoon angioplasty broadens the role of primary angioplasty and reduces adjuvant stenting in complex superficial femoral artery lesions</TI>
<SO>Journal of the American College of Surgeons</SO>
<YR>2008</YR>
<VL>206</VL>
<NO>3</NO>
<PG>524-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banerjee-2009" MODIFIED="2013-04-11 10:58:02 +0100" MODIFIED_BY="[Empty name]" NAME="Banerjee 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-04-11 10:58:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banerjee S, Brilakis ES, Das TS, Lichtenwalter CS</AU>
<TI>Treatment of complex superficial femoral artery lesions with PolarCath cryoplasty</TI>
<SO>American Journal of Cardiology</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>3</NO>
<PG>447-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basco-2012" MODIFIED="2013-03-06 09:50:05 +0000" MODIFIED_BY="[Empty name]" NAME="Basco 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-03-06 09:50:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basco MT, Schlösser FJ, Muhs BE, Indes JE, Blume PA, Key JJ, et al</AU>
<TI>Lower extremity limb salvage with cryoplasty: a single-center cohort study</TI>
<SO>Vascular</SO>
<YR>2012</YR>
<VL>20</VL>
<NO>1</NO>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosiers-2010" MODIFIED="2013-03-07 07:48:31 +0000" MODIFIED_BY="[Empty name]" NAME="Bosiers 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-07 07:48:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosiers M, Deloose K, Vermassen F, Schroë H, Lauwers G, Lansinck W, et al</AU>
<TI>The use of the cryoplasty technique in the treatment of infrapopliteal lesions for critical limb ischemia patients in a routine hospital setting: one-year outcome of the Cryoplasty CLIMB Registry</TI>
<SO>The Journal of Cardiovascular Surgery (Torino)</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>2</NO>
<PG>193-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Das-2009" MODIFIED="2013-03-06 09:59:09 +0000" MODIFIED_BY="[Empty name]" NAME="Das 2009" YEAR="2006">
<REFERENCE MODIFIED="2013-03-06 09:56:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Das T, McNamara T, Gray B, Sedillo GJ, Turley BR, Kollmeyer K, et al</AU>
<TI>Cryoplasty therapy for limb salvage in patients with critical limb ischemia</TI>
<SO>Journal of Endovascular Therapy</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>6</NO>
<PG>753-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-06 09:59:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Das TS, McNamara T, Gray B, Sedillo GJ, Turley BR, Kollmeyer K, et al</AU>
<TI>Primary cryoplasty therapy provides durable support for limb salvage in critical limb ischemia patients with infrapopliteal lesions: 12-month follow-up results from the BTK Chill Trial</TI>
<SO>Journal of Endovascular Therapy</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>2 Suppl 2</NO>
<PG>II19-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>McNamara TO, Anaya C, Quinn BJ</AU>
<TI>Interim results of cryoplasty in the below-the-knee CHILL study</TI>
<SO>Society of Interventional Radiology Annual Scientific Meeting</SO>
<YR>2007</YR>
<PG>Abstract 110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>McNamara TO, Anaya CA, Quinn BJ</AU>
<TI>Interim results of cryoplasty in the below-the-knee CHILL study</TI>
<SO>Society of Interventional Radiology Annual Scientific Meeting</SO>
<YR>2006</YR>
<PG>Abstract 3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fava-2004" MODIFIED="2013-07-12 08:10:39 +0100" MODIFIED_BY="[Empty name]" NAME="Fava 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-07-12 08:10:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fava M, Loyola S, Polydorou A, Papapavlou P, Polydorou A, Mendiz O, et al</AU>
<TI>Cryoplasty for femoropopliteal arterial disease: late angiographic results of initial human experience</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1239-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-FIX_x002d_IT-Retro" MODIFIED="2013-03-27 12:38:40 +0000" MODIFIED_BY="[Empty name]" NAME="FIX-IT Retro" YEAR="2007">
<REFERENCE MODIFIED="2013-03-27 12:38:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Clinical outcomes of three different percutaneous revascularization strategies for the treatment of lifestyle limiting claudication: a retrospective analysis (FIX-IT Retro)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00512720?term=NCT00512720&amp;rank=1 (access 26 March 2013)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-03-12 13:40:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-12 13:40:47 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00512720"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gisbertz-2009" MODIFIED="2013-03-06 10:11:58 +0000" MODIFIED_BY="[Empty name]" NAME="Gisbertz 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-03-06 10:11:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gisbertz SS, de Borst GJ, Overtoom TT, Moll FL, de Vries JP</AU>
<TI>Initial results of concomitant cryoplasty after remote endarterectomy of the superficial femoral artery: a feasibility study (cryoplasty following remote endarterectomy)</TI>
<SO>Vascular and Endovascular Surgery</SO>
<YR>2010</YR>
<VL>44</VL>
<NO>1</NO>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalo-2010" MODIFIED="2013-03-06 10:15:00 +0000" MODIFIED_BY="[Empty name]" NAME="Gonzalo 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-06 10:15:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalo B, Solanich T, Bellmunt S, Herranz C, González E, Arnedo G, et al</AU>
<TI>Cryoplasty as endovascular treatment in the femoropopliteal region: hemodynamic results and follow-up at one year</TI>
<SO>Annals of Vascular Surgery</SO>
<YR>2010</YR>
<VL>24</VL>
<NO>5</NO>
<PG>680-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karthik-2007" NAME="Karthik 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karthik S, Tuite DJ, Nicholson AA, Patel JV, Shaw DR, McPherson SJ, et al</AU>
<TI>Cryoplasty for arterial restenosis</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>40-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korteweg-2009" MODIFIED="2013-08-07 03:34:14 +0100" MODIFIED_BY="[Empty name]" NAME="Korteweg 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-08-07 03:34:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korteweg MA, van Gils M, Hoedt MT, van der Valk PH, Tutein Noltenius RP, Avontuur JA, et al</AU>
<TI>Cryoplasty for occlusive disease of the femoropopliteal arteries: 1-year follow-up</TI>
<SO>Cardiovascular and Interventional Radiology</SO>
<YR>2009</YR>
<VL>32</VL>
<NO>2</NO>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laird-2006" MODIFIED="2013-08-07 03:35:15 +0100" MODIFIED_BY="[Empty name]" NAME="Laird 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-07-12 08:03:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laird J, Jaff MR, Biamino G, McNamara T, Scheinert D, Zetterlund P, et al</AU>
<TI>Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry</TI>
<SO>Journal of Vascular Interventional Radiology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>8</NO>
<PG>1067-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-07 03:35:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Laird JR, Biamino G, McNamara T, Schneidert D, Zetterlund P, Moen E, et al</AU>
<TI>Cryoplasty for the treatment of femoropopliteal arterial disease: extended follow-up results</TI>
<SO>Journal of Endovascular Therapy</SO>
<YR>2006</YR>
<VL>13 Suppl II</VL>
<PG>II52-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samson-2008" MODIFIED="2013-05-29 13:03:54 +0100" MODIFIED_BY="[Empty name]" NAME="Samson 2008" YEAR="2007">
<REFERENCE MODIFIED="2013-03-06 10:24:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samson RH, Schowalter DP, Lepore MR Jr, Ames S</AU>
<TI>CryoPlasty therapy of the superficial femoral and popliteal arteries: a single centre experience</TI>
<SO>Vascular and Endovascular Surgery</SO>
<YR>2007</YR>
<VL>40</VL>
<NO>6</NO>
<PG>446-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-29 13:03:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Samson RH, Showalter DP, Lepore M Jr, Nair DG, Merigliano K</AU>
<TI>CryoPlasty therapy of the superficial femoral and popliteal arteries: a reappraisal after 44 months' experience</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2008</YR>
<VL>48</VL>
<NO>3</NO>
<PG>634-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmieder-2010" MODIFIED="2013-03-06 12:31:13 +0000" MODIFIED_BY="[Empty name]" NAME="Schmieder 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-06 12:31:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmieder GC, Carroll M, Panneton JM</AU>
<TI>Poor outcomes with cryoplasty for lower extremity occlusive disease</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2010</YR>
<VL>52</VL>
<NO>2</NO>
<PG>362-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shin-2010" MODIFIED="2013-03-07 07:50:26 +0000" MODIFIED_BY="[Empty name]" NAME="Shin 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-03-07 07:50:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shin SH, Baril D, Chaer R, Makaroun M, Rhee R, Marone L</AU>
<TI>Cryoplasty offers no advantage over standard balloon angioplasty for the treatment of in-stent restenosis</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2010</YR>
<VL>52</VL>
<NO>3</NO>
<PG>803-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silva-2011" MODIFIED="2013-03-06 12:39:27 +0000" MODIFIED_BY="[Empty name]" NAME="Silva 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-03-06 12:39:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silva GV, Fernandes MR, Cardoso CO, Miranda WR, Strickman N, Mortazavi A, et al</AU>
<TI>Cryoplasty for peripheral artery disease in an unselected patient population in a tertiary center</TI>
<SO>Texas Heart Institute Journal</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>2</NO>
<PG>122-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-12-03 14:00:06 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2013-07-26 08:12:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ATHERO" MODIFIED="2013-07-26 08:12:01 +0100" MODIFIED_BY="[Empty name]" NAME="ATHERO" YEAR="">
<REFERENCE MODIFIED="2013-03-26 21:23:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>ATHERO: Advanced technology halting early re-stenosis and occlusion</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00407940?term=NCT00407940&amp;rank=1 (accessed 26 March 2013)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-15 09:05:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-14 11:19:35 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00407940"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-The-SFA-Study-CLASE" MODIFIED="2013-03-26 21:23:17 +0000" MODIFIED_BY="[Empty name]" NAME="The SFA Study CLASE" YEAR="2009">
<REFERENCE MODIFIED="2013-03-26 21:23:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Prime time for superficial femoral artery (SFA) - The SFA study (CLASE)</TI>
<SO>http://clinicaltrials.gov/ct2/show/NCT00902317?term=NCT00902317&amp;rank=1 (accessed 26 March 2013)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-14 10:47:39 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-14 10:47:29 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00902317"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-08-07 03:37:57 +0100" MODIFIED_BY="Heather  Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2013-08-07 03:37:57 +0100" MODIFIED_BY="Heather  Maxwell">
<REFERENCE ID="REF-Adar-1989" MODIFIED="2008-08-12 15:03:26 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Adar 1989" TYPE="JOURNAL_ARTICLE">
<AU>Adar R, Critchfield GC, Eddy DM</AU>
<TI>A confidence profile analysis of the results of femoropopliteal percutaneous transluminal angioplasty in the treatment of lower-extremity ischemia</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>1</NO>
<PG>57-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clowes-1983" MODIFIED="2008-08-12 15:03:30 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Clowes 1983" TYPE="JOURNAL_ARTICLE">
<AU>Clowes AW, Reidy MA, Clowes MM</AU>
<TI>Mechanisms of stenosis after arterial injury</TI>
<SO>Laboratory Investigation</SO>
<YR>1983</YR>
<VL>49</VL>
<NO>2</NO>
<PG>208-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dewhurst-1991" MODIFIED="2013-03-07 07:52:00 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Dewhurst 1991" TYPE="JOURNAL_ARTICLE">
<AU>Dewhurst G, Wood DA, Walker F, Lampe FC, Jeffreys M, Cooper M, et al</AU>
<TI>A population survey of cardiovascular disease in elderly people: design, methods and prevalence results</TI>
<SO>Age and Ageing</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>5</NO>
<PG>353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dilley-1988" MODIFIED="2013-03-06 12:49:17 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Dilley 1988" TYPE="JOURNAL_ARTICLE">
<AU>Dilley RJ, McGeachie JK, Prendergast FJ</AU>
<TI>A review of the histologic changes in vein-to-artery grafts, with particular reference to intimal hyperplasia</TI>
<SO>Archives of Surgery</SO>
<YR>1988</YR>
<VL>123</VL>
<NO>6</NO>
<PG>691-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dormandy-1991" MODIFIED="2008-08-12 15:03:43 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Dormandy 1991" TYPE="JOURNAL_ARTICLE">
<AU>Dormandy JA, Murray GD</AU>
<TI>The fate of the claudicant--a prospective study of 1969 claudicants</TI>
<SO>European Journal of Vascular Surgery</SO>
<YR>1991</YR>
<VL>5</VL>
<NO>2</NO>
<PG>131-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowkes-1991" MODIFIED="2008-08-12 15:03:47 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Fowkes 1991" TYPE="JOURNAL_ARTICLE">
<AU>Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ</AU>
<TI>Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>2</NO>
<PG>384-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowkes-2001" MODIFIED="2013-03-06 12:55:00 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Fowkes 2001" TYPE="COCHRANE_REVIEW">
<AU>Fowkes FG, Gillespie IN</AU>
<TI>Angioplasty (versus non surgical management) for intermittent claudication</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-12-03 14:22:13 +0000" MODIFIED_BY="Heather  Maxwell">
<IDENTIFIER MODIFIED="2012-12-03 14:22:13 +0000" MODIFIED_BY="Heather  Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD000017"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gage-1967" MODIFIED="2013-03-07 07:52:11 +0000" MODIFIED_BY="[Empty name]" NAME="Gage 1967" TYPE="JOURNAL_ARTICLE">
<AU>Gage A, Fazekas G, Riley EE Jr</AU>
<TI>Freezing injury to large blood vessels in dogs. With comments on the effect of experimental freezing of bile ducts</TI>
<SO>Surgery</SO>
<YR>1967</YR>
<VL>61</VL>
<NO>5</NO>
<PG>748-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grassl-2005" NAME="Grassl 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grassl ED, Bischof JC</AU>
<TI>In vitro model systems for evaluation of smooth muscle cell response to cryoplasty</TI>
<SO>Cryobiology</SO>
<YR>2005</YR>
<VL>50</VL>
<NO>2</NO>
<PG>162-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-03-06 13:00:16 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsch-2001" MODIFIED="2013-07-04 15:38:19 +0100" MODIFIED_BY="[Empty name]" NAME="Hirsch 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al</AU>
<TI>Peripheral arterial disease detection, awareness, and treatment in primary care</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>286</VL>
<NO>11</NO>
<PG>1317-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karthik-2007a" MODIFIED="2013-04-23 11:49:13 +0100" MODIFIED_BY="[Empty name]" NAME="Karthik 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Karthik S, Kessel DO</AU>
<TI>Cryoplasty &#8211; where is the evidence?</TI>
<SO>Acta Chirurgica Belgica</SO>
<YR>2007</YR>
<VL>107</VL>
<NO>5</NO>
<PG>500-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessel-2008" MODIFIED="2013-04-11 11:03:20 +0100" MODIFIED_BY="[Empty name]" NAME="Kessel 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kessel DO, Samson RH</AU>
<TI>What is the evidence for the efficacy of cryoplasty?</TI>
<SO>Journal of Cardiovascular Surgery</SO>
<YR>2008</YR>
<VL>49</VL>
<NO>2</NO>
<PG>179-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leu-1999" MODIFIED="2008-08-12 15:03:53 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Leu 1999" TYPE="JOURNAL_ARTICLE">
<AU>Leu AJ, Schneider E, Canova CR, Hoffmann U</AU>
<TI>Long-term results after recanalisation of chronic iliac artery occlusions by combined catheter therapy without stent placement</TI>
<SO>European Journal of Vascular and Endovascular Surgery</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>6</NO>
<PG>499-505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leville-2006" MODIFIED="2013-07-04 15:39:11 +0100" MODIFIED_BY="[Empty name]" NAME="Leville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Leville CD, Kashyap VS, Clair DG, Bena JF, Lyden SP, Greenberg RK, et al</AU>
<TI>Endovascular management of iliac artery occlusions: extending treatment to TransAtlantic Inter-Society Consensus class C and D patients</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2006</YR>
<VL>43</VL>
<NO>1</NO>
<PG>32-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-London-1995" MODIFIED="2013-03-06 13:02:33 +0000" MODIFIED_BY="Heather  Maxwell" NAME="London 1995" TYPE="JOURNAL_ARTICLE">
<AU>London NJ, Varty K, Sayers RD, Thompson MM, Bell PR, Bolia A</AU>
<TI>Percutaneous transluminal angioplasty for lower-limb critical ischaemia</TI>
<SO>British Journal of Surgery</SO>
<YR>1995</YR>
<VL>82</VL>
<NO>9</NO>
<PG>1232-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Long-1991" MODIFIED="2008-08-12 15:04:01 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Long 1991" TYPE="JOURNAL_ARTICLE">
<AU>Long AL, Page PE, Raynaud AC, Beyssen BM, Fiessinger JN, Ducimetiere P, et al</AU>
<TI>Percutaneous iliac artery stent: angiographic long-term follow-up</TI>
<SO>Radiology</SO>
<YR>1991</YR>
<VL>180</VL>
<NO>3</NO>
<PG>771-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-1995" MODIFIED="2008-08-12 15:04:04 +0100" MODIFIED_BY="Heather  Maxwell" NAME="Martin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Martin EC, Katzen BT, Benenati JF, Diethrich EB, Dorros G, Graor RA, et al</AU>
<TI>Multicenter trial of the wallstent in the iliac and femoral arteries</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>6</NO>
<PG>843-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mintz-1996" MODIFIED="2013-03-06 13:06:53 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Mintz 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, et al</AU>
<TI>Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study</TI>
<SO>Circulation</SO>
<YR>1996</YR>
<VL>94</VL>
<NO>1</NO>
<PG>35-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1995" MODIFIED="2013-03-06 13:08:19 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Murphy 1995" TYPE="JOURNAL_ARTICLE">
<AU>Murphy KD, Encarnacion CE, Le VA, Palmaz JC</AU>
<TI>Iliac artery stent placement with the Palmaz stent: follow-up study</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>1995</YR>
<VL>6</VL>
<NO>3</NO>
<PG>321-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-2005" MODIFIED="2013-07-04 15:42:01 +0100" MODIFIED_BY="[Empty name]" NAME="Park 2005" TYPE="JOURNAL_ARTICLE">
<AU>Park KB, Do YS, Kim JH, Han YH, Kim DI, Kim DK, et al</AU>
<TI>Stent placement for chronic iliac arterial occlusive disease: the results of 10 years experience in a single institution</TI>
<SO>Korean Journal of Radiology</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>256-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-2007" MODIFIED="2013-08-07 03:37:57 +0100" MODIFIED_BY="[Empty name]" NAME="Park 2007" TYPE="JOURNAL_ARTICLE">
<AU>Park KB, Do YS, Kim DI, Kim DK, Kim YW, Shin SW, et al</AU>
<TI>The TransAtlantic InterSociety Consensus (TASC) classification system in iliac arterial stent placement: long-term patency and clinical limitations</TI>
<SO>Journal of Vascular and Interventional Radiology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>2</NO>
<PG>193-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prasad-2012" MODIFIED="2013-03-06 13:12:06 +0000" MODIFIED_BY="[Empty name]" NAME="Prasad 2012" TYPE="JOURNAL_ARTICLE">
<AU>Prasad A</AU>
<TI>Post-dilation of superficial femoral artery stents with cryoplasty: does the COBRA trial take a bite out of diabetic restenosis?</TI>
<SO>Journal of American College of Cardiology</SO>
<YR>2012</YR>
<VL>60</VL>
<NO>15</NO>
<PG>1360-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sottiurai-1983" MODIFIED="2013-03-06 13:12:26 +0000" MODIFIED_BY="Heather  Maxwell" NAME="Sottiurai 1983" TYPE="JOURNAL_ARTICLE">
<AU>Sottiurai VS, Yao JS, Flinn WR, Batson RC</AU>
<TI>Intimal hyperplasia and neointima: an ultrastructural analysis of thrombosed grafts in humans</TI>
<SO>Surgery</SO>
<YR>1983</YR>
<VL>93</VL>
<NO>6</NO>
<PG>809-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2007" MODIFIED="2013-07-04 15:42:19 +0100" MODIFIED_BY="[Empty name]" NAME="White 2007" TYPE="JOURNAL_ARTICLE">
<AU>White CJ, Gray WA</AU>
<TI>Endovascular therapies for peripheral arterial disease: an evidence-based review</TI>
<SO>Circulation</SO>
<YR>2007</YR>
<VL>116</VL>
<NO>19</NO>
<PG>2203-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wildgruber-2008" MODIFIED="2013-04-11 11:04:36 +0100" MODIFIED_BY="[Empty name]" NAME="Wildgruber 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wildgruber MG, Berger HJ</AU>
<TI>Cryoplasty for the prevention of arterial restenosis</TI>
<SO>Cardiovascular and Interventional Radiology</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>6</NO>
<PG>1050-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-05-19 12:56:41 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-McCaslin-2007" MODIFIED="2013-05-19 12:56:41 +0100" MODIFIED_BY="[Empty name]" NAME="McCaslin 2007" TYPE="COCHRANE_REVIEW">
<AU>McCaslin JE, Macdonald S, Stansby G</AU>
<TI>Cryoplasty for peripheral vascular disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-12-15 09:02:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-15 09:02:10 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005507.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-12-03 14:19:44 +0000" MODIFIED_BY="Karen Welch"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-08-08 11:55:54 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-08-08 11:55:54 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-08-07 05:52:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Banerjee-2012">
<CHAR_METHODS MODIFIED="2013-08-07 05:34:15 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, multicentre clinical evaluation of the PolarCath® system versus conventional balloon post-dilation of nitinol self-expanding stents (nSES) implanted in the superficial femoral artery (SFA) of patients with diabetes mellitus, presenting with life-style limiting claudication</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 05:52:34 +0100" MODIFIED_BY="[Empty name]">
<P>No of participants: 74 patients with 90 stented SFA lesions (45 randomised to receive cryoplasty, and 45 received conventional angioplasty)</P>
<P>Country: USA</P>
<P>Inclusion criteria<BR/>1. Diabetics, insulin or non-insulin dependent above 21 years of age, able to provide an informed consent, and life expectancy &gt; 1 year</P>
<P>2. Presenting with moderate claudication (Rutherford stage 2), severe intermittent claudication (RB stage 3), chronic critical limb ischaemia with rest pain (RB stage 4), or chronic critical limb ischaemia with ischaemic ulcers (RB stage 5)<BR/>3. Placement of &gt; 5 mm in diameter self-expanding nitinol stent in the SFA, with at least 1 vessel infra-popliteal run-off</P>
<P>4. Placement of &gt; 60 mm in length self-expanding nitinol stent in the SFA, with at least 1 vessel infra-popliteal run-off</P>
<P>Exclusion criteria<BR/>1. Serum creatinine &#8805; 2.0 mg/dl<BR/>2. Absence of at least 1 vessel brisk infra-popliteal run-off to the foot<BR/>3. LV ejection fraction &#8804; 25%<BR/>4. Allergy to iodinated contrast<BR/>5. Allergy to aspirin or clopidogrel<BR/>6. Relative or absolute contraindication to anticoagulation<BR/>7. WBC &lt; 3000 K/UL; platelet count &lt; 100,000 K/UL; Hgb &lt; 10 g/dl</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:22:13 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: Cryoplasty</P>
<P>Control: Conventional balloon angioplasty</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-13 11:11:08 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome:</P>
<P>Rate of binary restenosis, at 12 months, as determined by duplex ultrasound.</P>
<P>Secondary outcome:</P>
<P>Resting ankle-brachial index (at 6 months and 1 year)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-07 05:48:38 +0100" MODIFIED_BY="[Empty name]">
<P>Location: superficial femoral artery</P>
<P>All patients received stents in both arms of the trial (74 patients with 90 stented lesions)</P>
<P>Outcomes were reported as:</P>
<UL>
<LI>per patient: limb loss, immediate success of procedures, cardiovascular deaths, deaths, complications, ABI, mean walking impairment scores, Rutherford stages</LI>
<LI>per lesion: binary restenosis, patency, immediate success of procedures</LI>
</UL>
<P>Antiplatelet/anticoagulant agents (clopidogrel, aspirin, warfarin) used by patients in both groups at randomisation, but no information is given regarding the usage of these agents during the trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 11:55:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diaz-2011">
<CHAR_METHODS MODIFIED="2013-08-07 05:39:31 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Eighty-six patients were randomised according to the operator&#8217;s preference to receive cryoplasty, and 69 received conventional angioplasty</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 11:55:28 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Spain</P>
<P>No of participants: 155 patients (86 randomised to receive cryoplasty, and 69 received conventional angioplasty). The cryoplasty group had 39 lesions at 29 sites (19 superficial femoral artery and 10 popliteal artery), while the angioplasty group had 45 lesions at 31 sites (22 superficial femoral artery and 9 popliteal artery)</P>
<P>Inclusion criteria: lifestyle-limiting claudication (Rutherford-Becker categories 1&#8211;3), and rest pain or ischaemic skin changes of the feet (Rutherford- Becker categories 4&#8211;5) induced by atheromatous lesions involving the femoropopliteal region</P>
<P>Exclusion criteria: patients with contraindications to the administration of contrast and patients with renal failure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-06 13:22:35 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: Cryoplasty</P>
<P>Control: Conventional balloon angioplasty</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-07 05:41:06 +0100" MODIFIED_BY="[Empty name]">
<P>The primary study endpoint was target lesion patency<BR/>Secondary endpoints were initial treatment success with &gt; 30% residual stenosis, absence of haemodynamically relevant dissection, and recoil without the need for stent placement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-07 05:46:16 +0100" MODIFIED_BY="[Empty name]">
<P>Location: femoropopliteal arteries</P>
<P>Patients from both arms of the trial received stents in case of &gt; 30% residual stenosis or luminal narrowing by dissection was detected</P>
<P>Outcomes were reported as:</P>
<UL>
<LI>per patient: patency, target lesion patency, need for re-intervention, immediate success of procedures, deaths, complications, ABI</LI>
<LI>per lesion: restenosis, need for re-intervention, immediate success of procedures</LI>
</UL>
<P>Information on antiplatelet/anticoagulant agents used by patients before enrolment in the study is not given. All patients received heparin intra-arterially before the procedure and a loading dose of clopidogrel on the day of the intervention. At discharge, a lifetime regimen of oral acetylsalicylic acid and an 8-week regimen of clopidogrel was prescribed.</P>
<P>Author sent additional data by e-mail</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-07 11:11:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fossaceca-2011">
<CHAR_METHODS MODIFIED="2013-08-07 05:43:19 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Twenty-four patients were allocated to receive cryoplasty, and 24 received conventional angioplasty</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 05:44:51 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy</P>
<P>No of participants: 48 patients (24 patients were allocated to receive cryoplasty, and 24 received conventional angioplasty). The cryoplasty group had 39 lesions located at 29 sites, while conventional angioplasty group had 45 lesions located at 31 sites</P>
<P>Inclusion criteria:</P>
<P>diabetes mellitus and peripheral atherosclerotic disease with severe claudication or CLI (Rutherford stages 2-6); haemodynamically significant stenosis (70%) or occlusion of the superficial femoral artery (SFA) and/or popliteal artery (PA) as assessed by preliminary colour Doppler ultrasound (CDUS)</P>
<P>Exclusion criteria:</P>
<P>patients with a history of severe allergy or hypersensitivity to contrast material, intolerance to aspirin and/or clopidogrel, coagulation disorders, acute ischaemia of the lower limbs, Buerger&#8217;s disease, deep vein thrombosis, loss of infected tissue and absence of outflow</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-08 14:52:42 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: Cryoplasty</P>
<P>Control: percutaneous angioplasty</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-07 05:53:12 +0100" MODIFIED_BY="[Empty name]">
<P>The primary study endpoints were immediate technical success (residual restenosis &lt; 30%) and distal run-off as assessed on post-procedural angiography, and degree of restenosis and distal run-off at 6 and 12 months, as assessed with either colour Doppler ultrasound (CDUS) or digital subtraction angiography (DSA)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-07 11:11:11 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Femoropopliteal arteries. The cryoplasty group had 29 sites (19 SFA, 10 PA) and 39 lesions for 24 patients, while the percutaneous angioplasty group had 31 sites (22 SFA, 9 PA) and 45 lesions for 24 patients.</P>
<P>Treatment failures were defined as lesions requiring additional conventional balloon angioplasty owing to a suboptimal result or requiring stent placement due to vessel dissection, and were not considered in the follow-up.</P>
<P>Outcomes were reported as</P>
<UL>
<LI>per site: patency, (re)stenosis, occlusion, immediate success of procedures</LI>
<LI>per patient: deaths</LI>
</UL>
<P>All patients were premedicated with aspirin and clopidogrel for at least 3 days before the procedure. No information is given about the antiplatelet/anticoagulants agents after the procedure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-07 11:11:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jahnke-2010">
<CHAR_METHODS MODIFIED="2013-02-27 11:52:38 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Sealed envelope containing the treatment modality<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 11:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany</P>
<P>No. of participants: 86 (40 Cryoplasty; 46 Conventional angioplasty)</P>
<P>Inclusion criteria:</P>
<P>lifestyle-limiting claudication (Rutherford-Becker categories 1-3); rest pain; ischaemic skin changes of the feet (Rutherford-Becker categories 4-5) induced by focal atherosclerotic stenoses or occlusions of the popliteal artery</P>
<P>Exclusion criteria:</P>
<P>haemodynamically relevant lesions (&gt; 50% luminal stenosis) of the arterial in- and/or outflow; previous stent or stent-graft placement into the popliteal artery; lesions induced by former vascular surgery; fresh embolic occlusions; contraindications to the administration of contrast media; renal failure; hyperthyroidism; allergic diathesis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 13:25:40 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: Cryoplasty </P>
<P>Control: Conventional balloon angioplasty </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-11 15:13:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: target lesion patency</P>
<P>Secondary outcomes: initial anatomic treatment success with &lt; 30% residual stenosis; absence of haemodynamically relevant dissection or recoil without the need for stent placement; complications</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-07-11 15:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Popliteal artery</P>
<P>The rate of stent placement for dissection and/or residual stenosis was 30% after cryoplasty and 39% after conventional angioplasty.</P>
<P>Outcomes were reported as:</P>
<UL>
<LI>per patient: patency, target lesion patency, restenosis, need for re-intervention, immediate success of procedures, complications, ABI</LI>
</UL>
<P>No information is given about antiplatelet/anticoagulation agents either before or after procedure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 11:55:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shammas-2012">
<CHAR_METHODS MODIFIED="2012-12-12 14:22:53 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Sealed envelope containing the treatment modality<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-08 11:55:54 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA</P>
<P>No. of participants: 40 (20 Cryoplasty; 20 Primary balloon angioplasty)</P>
<P>Inclusion criteria:</P>
<P>patients had de novo lesions, were &gt; 18 years of age and referred for claudication (Rutherford Becker I&#8211;III) or critical limb ischaemia (Rutherford Becker IV&#8211;V)</P>
<P>Exclusion criteria:</P>
<P>1. heavily calcified vessels (as subjectively determined by the operator)</P>
<P>2. total occlusions longer than 10 cm, any lesion less than 3 cm, or non-femoropopliteal lesions</P>
<P>3. inability to take aspirin or adenosine diphosphate receptor antagonists</P>
<P>4. bleeding disorder or platelet count less than 100,000 per &#956;l</P>
<P>5. creatinine over 3.5 mg/dl</P>
<P>6. unwilling to give consent or return for future follow-up visits</P>
<P>7. decompensated congestive heart failure or acute coronary syndrome</P>
<P>8. staged vascular procedure during the same hospital stay or one week after the index procedure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-21 10:51:41 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: Cryoplasty</P>
<P>Control: Primary balloon angioplasty</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-07 11:15:02 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: target lesion revascularisation at 6 months</P>
<P>Secondary outcomes:</P>
<P>1. The rate of bail out stenting because of suboptimal acute angiographic results defined as a residual stenosis of &#8805; 30% or the presence of type C&#8211;F dissection. Dissections were classified according to the National Heart, Lung, and Blood Institute classification for coronary artery dissections<BR/>2. Final acute angiographic results in each arm at the end of the procedure<BR/>3. Target vessel revascularisation (TVR) at 6 months<BR/>4. Major adverse events including major amputation, death, distal embolisation, vascular complications (arteriovenous fistula, pseudoaneurysm, or perforation), major bleeding (loss of 3 units of packed red blood cells with a source of bleed, or intracranial bleed or retroperitoneal bleed), unplanned urgent revascularisation of the treated vessel in the same hospital stay, stroke, and acute renal failure (an increase in creatinine clearance by 25% over pre procedure baseline)<BR/>5. Change in the ankle brachial index at 6 month post procedure from baseline.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-06-11 13:54:28 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Femoropopliteal arteries</P>
<P>Bailout stenting was performed in patients with procedural failures, but were not permitted for procedural success.</P>
<P>Outcomes were reported as</P>
<UL>
<LI>per patient: restenosis, limb loss, deaths, complications, ABI</LI>
<LI>per lesion restenosis, need for re-intervention, immediate success of procedures</LI>
</UL>
<P>Clopidogrel 600 mg and aspirin 324 mg were administered orally immediately prior to the procedure in patients not taking antiplatelet agents. Patients already receiving clopidogrel and aspirin continued to take 75 mg oral clopidogrel and 324 mg oral aspirin daily. The exclusive anticoagulant administered during the procedure was intravenous bivalirudin.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-08 11:50:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spiliopoulos-2010">
<CHAR_METHODS MODIFIED="2013-02-26 15:07:29 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Allocation: pooled 1:1 envelopes, which were opened only after lesions were successfully crossed</P>
<P>Blinded: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 11:18:20 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Greece</P>
<P>No. of participants: 50 (24 Cryoplasty; 26 Conventional balloon angioplasty)</P>
<P>Inclusion criteria:</P>
<P>non-insulin or insulin dependent diabetes mellitus; severe claudication or CLI (Rutherford stage 3 to 6); stenosis &#8805; 70% or occlusion of the SFA and/or the PFA; de novo and ISR lesions</P>
<P>Exclusion criteria:</P>
<P>diet-controlled diabetes; history of severe contrast allergy or hypersensitivity; intolerance to aspirin and/or clopidogrel; systemic coagulopathy or hypercoagulation disorders; acute limb ischaemia; Buerger disease; deep vein thrombosis; infected tissue loss; absent pedal arch run-off</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-08 11:50:44 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: Cryoplasty</P>
<P>Control: Conventional balloon angioplasty using commercially available semi-compliant or non-compliant balloon catheters</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-07-11 15:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: technical success &lt; 30% residual stenosis without any adjunctive stenting; primary patency; binary in-lesion restenosis (&gt; 50%); freedom from target lesion recanalisation</P>
<P>Secondary outcome: 30-day complications; patient mortality; limb salvage; minor amputation of the treated limbs</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-07 11:19:24 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Femoropopliteal arteries</P>
<P>Stenting was reserved for bail-out in case of elastic recoil, post-dilatation residual stenosis 30%, or<BR/>severe flow-limiting dissection (type C). Technical success was defined as 30% residual stenosis without any adjunctive stenting.</P>
<P>Outcomes were reported as</P>
<UL>
<LI>per patient: limb loss, deaths</LI>
<LI>per lesion: binary restenosis, need for re-intervention, immediate success of procedures</LI>
</UL>
<P>No information is given on the usage of antiplatelet/anticoagulant agents before the patients' enrolment in the study.</P>
<P>All patients were premedicated with aspirin and clopidogrel for at least 3 days before the procedure. After procedure, patients received were prescribed with a dual antiplatelet therapy (aspirin and clopidogrel) for 6 weeks and solely clopidogrel or aspirin indefinitely thereafter.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-07 11:22:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2011">
<CHAR_METHODS MODIFIED="2013-08-07 11:20:44 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
<P>Patients with peripheral arterial disease (PAD) of the iliac or infra-inguinal arteries or lower limb bypass graft stenoses</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 11:22:02 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China</P>
<P>No. of participants: 25 (10 Cryoplasty; 15 Conventional balloon angioplasty)</P>
<P>Inclusion criteria:</P>
<P>1. Diagnosed with atherosclerotic peripheral arterial disease according to the Trans-Atlantic Inter-Society Consensus (TASC) classification</P>
<P>2. With lesions involving the iliac and femoropopliteal regions, but having no outflow tract obstruction below the knee</P>
<P>3. With Fontaine class II and greater</P>
<P>4. ABI &lt; 0.6</P>
<P>5. TcPO<SUB>2</SUB> &lt; 30 mmHg</P>
<P>Definite atherosclerotic plaque formation, haemodynamically significant stenosis (&gt; 50%) or total occlusion of the arteries, as documented by CDFI, CTA or MRA</P>
<P>Exclusion criteria:</P>
<P>1. Acute limb ischaemia/thrombus formation</P>
<P>2. Previous bypass surgery or stenting procedures</P>
<P>3. With outflow tract narrowing or total obstruction below the knee</P>
<P>4. Intolerance to contrast</P>
<P>5. History of  contrast allergy or hypersensitivity and intolerance to antiplatelet and/or anticoagulation drugs</P>
<P>6. Infected tissue loss</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 12:39:05 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: Cryoplasty</P>
<P>Control: Conventional balloon angioplasty</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-04-11 09:40:24 +0100" MODIFIED_BY="[Empty name]">
<P>1. Technical success: residual stenosis &lt; 30%</P>
<P>2. Changes in clinical characteristics between baseline and follow-up; postoperative changes in clinical characteristics using Rutherford classification 7</P>
<P>3. ABI</P>
<P>4. Arterial stenosis using  the colour Doppler flow image (CDFI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-07 11:22:54 +0100" MODIFIED_BY="[Empty name]">
<P>Location: Iliac or infrainguinal arteries</P>
<P>Outcomes were reported as</P>
<UL>
<LI>per patient: immediate success of procedures, complications, ABI</LI>
</UL>
<P>No information is given on the usage of antiplatelet/anticoagulant agents before or after the patients' enrolment in the study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-08-07 11:24:01 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-03-27 12:53:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bakken-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-27 12:53:47 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective review of patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-27 12:49:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Banerjee-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-27 12:49:23 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-10 11:08:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Basco-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-10 11:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 13:09:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosiers-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 13:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre registry evaluating the use of the PolarCath peripheral dilatation system</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-07 11:23:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Das-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-07 11:23:27 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial, but prospective, multicentre study of 111 patients with stenoses of occlusions of infrapopliteal vessels</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-07 11:23:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fava-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-07 11:23:37 +0100" MODIFIED_BY="[Empty name]">
<P>Case series of 15 patients with stenoses and/or occlusions of the SFA and PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 13:43:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FIX_x002d_IT-Retro">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 13:43:31 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective analysis </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-07 11:23:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gisbertz-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-07 11:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective cohort study of 17 patients treated with cryoplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-29 13:09:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gonzalo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-29 13:09:19 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective study of 11 patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-07 11:23:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karthik-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-07 11:23:51 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, single centre follow-up case series of arterial restenosis in 10 patients with graft risk or in stent restenosis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-07 11:23:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Korteweg-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-07 11:23:53 +0100" MODIFIED_BY="[Empty name]">
<P>Pilot study without a control arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-07 11:23:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laird-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-07 11:23:58 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective, multicentre registry of 102 claudicants with lesions of the SFA and PA. Results to nine months reported</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-07 11:24:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samson-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-07 11:24:01 +0100" MODIFIED_BY="[Empty name]">
<P>Case series of 47 lesions in 32 consecutive patients with lesions in the SFA, PA and vein bypass grafts</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-29 14:30:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmieder-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-29 14:30:29 +0000" MODIFIED_BY="[Empty name]">
<P> Retrospective review of patients </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-05 12:30:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shin-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-05 12:30:49 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective record review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-27 11:50:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Silva-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-27 11:50:56 +0000" MODIFIED_BY="[Empty name]">
<P>Retrospective analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PA: popliteal artery<BR/>SFA: superficial femoral artery</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-12-03 14:00:06 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-08-07 11:32:03 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-08-07 11:27:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ATHERO">
<CHAR_STUDY_NAME MODIFIED="2012-12-12 13:49:11 +0000" MODIFIED_BY="[Empty name]">
<P>ATHERO: Advanced technology halting early re-stenosis and occlusion</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-07-26 10:23:04 +0100" MODIFIED_BY="[Empty name]">
<P>Study design</P>
<P>Allocation: Randomised<BR/>Control: Active control<BR/>Endpoint classification: Safety/efficacy study<BR/>Intervention model: Parallel assignment<BR/>Masking: Open label<BR/>Primary purpose: Treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 11:26:08 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 100</P>
<P>Inclusion criteria:</P>
<P>- The subject must give written informed consent and possess decision making capacity free of sedative or hypnotic agents</P>
<P>- Age 18 years or older</P>
<P>- Candidate for angiography with intent to treat as determined by the principle investigator</P>
<P>- On angiography, ipsilateral to a symptomatic limb, a stenotic or occluded de novo or restenotic lesion in the common femoral artery, superficial femoral artery or above the knee popliteal artery measuring no longer than 10 cm (the upper limit of treatment in cryoplasty pre-marketing)</P>
<P>- On angiography lesion stenoses between 50% and 100% (inclusive)</P>
<P>- At least one run-off vessel - available for follow-up assessments</P>
<P>Exclusion criteria:</P>
<P>- Contraindication to systemic anticoagulation e.g. history of documented haemorrhage requiring treatment within the past 30 days; history of a hereditary bleeding disorder or known bleeding diathesis; major surgery or trauma, open chest massage, ocular surgery or haemorrhagic retinopathy within the past 30 days; puncture at a non-compressible site within 48 hours prior to planned procedure; history of stroke, intracranial haemorrhage, or central nervous system structural abnormalities within the past 3 months</P>
<P>- History of endovascular surgery procedure or open vascular surgery on the index limb within the last 30 days</P>
<P>- History of significant acute or chronic kidney disease that would preclude contrast angiography - known allergy to contrast agents</P>
<P>- History of heparin-induced thrombocytopenia (HIT)</P>
<P>- Participation in any study of an investigational device, medication, biologic, or other agent within 30 days prior to randomisation</P>
<P>- Any thrombolytic therapy within 30 days of randomisation</P>
<P>- Pregnancy, lactation, or possession of any child bearing potential without evidence of surgical infertility or passage of 12 months since the last day of the subject's last menstrual period</P>
<P>- Target lesion involving a Dacron prosthesis or a prosthetic of unknown material</P>
<P>- Target lesion extending into the orifice of the profunda femoris artery</P>
<P>- Prisoner status</P>
<P>- Any other subject feature that in the opinion of the investigator should preclude study participation</P>
<P>Age minimum: 18 years<BR/>Age maximum: N/A<BR/>Gender: Both</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-07 11:26:36 +0100" MODIFIED_BY="[Empty name]">
<P>Device: Lower extremity atherectomy and cryoplasty - Silverhawk&#8482; Atherectomy and CryoPlasty® Therapy for Lower Extremity Claudication</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-07 11:27:39 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes:</P>
<P>Primary target patency at 12 months. The 'target' is the index stenotic lesion(s). Primary patency is defined as &lt; 50% residual stenosis by duplex (colour-flow Doppler) scan analysis, with antegrade flow to the target vessel</P>
<P>Secondary outcomes:</P>
<P>Ankle-brachial index (ABI) improvement by = 0.15 at 3, 6 and 12 months compared to baseline</P>
<P>Change in walking impairment questionnaire (WIQ) functional status scores from baseline at 3, 6 and 12 months</P>
<P>Complications: defined as adverse events (AEs) or serious adverse events (SAEs). Complications may or may not be device related</P>
<P>Cost to patient and hospital: Including operating room times and duration of hospitalisation</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-14 11:24:29 +0000" MODIFIED_BY="[Empty name]">
<P>December 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-02-26 15:14:22 +0000" MODIFIED_BY="[Empty name]">
<P>Joshua I Greenberg, MD: Telephone: 619-543-6222</P>
<P>Email: jigreenberg@ucsd.edu (not a valid emailed address; 10 May 2012)</P>
<P>Ahmed Suliman, MD: Telephone: 619-543-6222</P>
<P>Email: asuliman@ucsd.edu (not a valid email address; 10 May 2012)</P>
<P>Principal Investigator: Niren Angle, MD; University of California, San Diego</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-08-07 11:27:58 +0100" MODIFIED_BY="[Empty name]">
<P>Still recruiting patients (as off 26 March 2013)</P>
<P>AA emailed: 20 December 2011; 10 May 2012 - emailed to N Angle; sent request http://www.niren-angle.com/Contact-Us.aspx on 31 January 2013</P>
<P>Other contact: Dr Niren Angle <A HREF="mailto:nangle@ucsd.edu">nangle@ucsd.edu</A> (not valid 10 May 2012); fherrera00@yahoo.com (from ResearchGate)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-08-07 11:32:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-The-SFA-Study-CLASE">
<CHAR_STUDY_NAME MODIFIED="2011-12-14 12:04:07 +0000" MODIFIED_BY="[Empty name]">
<P>A Randomized Trial for Femoropopliteal Arteries (Prime Time for Superficial Femoral Artery (SFA) - The SFA Study CLASE)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-12-12 14:00:24 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial</P>
<P>Allocation: Randomised</P>
<P>Endpoint classification: Safety/efficacy study</P>
<P>Intervention model: Parallel assignment</P>
<P>Masking: Double blind (subject, investigator)</P>
<P>Primary purpose: Treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-07 11:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>Number: 130</P>
<P>Inclusion criteria:</P>
<P>- Stenosis &gt; 70% or total occlusion of the femoropopliteal segment that do not include the origin of the SFA - SFA and popliteal of &gt; 4 mm in diameter</P>
<P>- TASC classification A, B, and C</P>
<P>- At least one vessel run-off</P>
<P>Exclusion criteria:</P>
<P>- Age &lt; 18 years old</P>
<P>- Medical condition that may cause the patient not to be compliant with follow-up (excl. terminal cancer)</P>
<P>- Pregnancy</P>
<P>- Unwilling or unable to comply with the follow-up</P>
<P>- Inability or refusal of informed consent</P>
<P>- Medical exclusion criteria - Systemic Infection (sepsis) - Bleeding diathesis unable to use anticoagulation. - Untreatable reaction to contrast material</P>
<P>- Anatomical endovascular exclusion criteria<B> </B>- SFA/popliteal artery &lt; 4 mm diameter - Total occlusion of femoral artery with non-visualization of the origin of the SFA - Previous SFA/popliteal intervention (PTA, stenting etc.) - Acute ischaemia and/or acute thrombosis of the SFA-popliteal segment - TASC type D</P>
<P>Age minimum: 18 years<BR/>Age maximum: N/A<BR/>Gender: Both</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-07-26 10:23:04 +0100" MODIFIED_BY="[Empty name]">
<P>Device: Viabahn endograft</P>
<P>Procedure: Angioplasty/stent (Guidant "Absolute" stent)</P>
<P>Procedure: Cryoplasty (PolarCath peripheral balloon catheter)</P>
<P>Procedure: Laser angioplasty (Spectranetics)</P>
<P>Procedure: SilverHawk Atherectomy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-07 11:31:50 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome(s):</P>
<P>Determine if the devices (laser, atherectomy, Polarcath, and Viabahn endograft) offer better treatment, better outcome, and better patency than the angioplasty/stent treatment to the femoral artery</P>
<P>Time frame: 2 weeks, 3, 6, and 12 months</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-12-14 12:04:48 +0000" MODIFIED_BY="[Empty name]">
<P>November 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-12-20 11:19:03 +0000" MODIFIED_BY="[Empty name]">
<P>Julio Rodriguez-Lopez, M.D.; Arizona Heart Institute </P>
<P>Email: jrodriguez@azheart.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-08-07 11:32:03 +0100" MODIFIED_BY="[Empty name]">
<P>Study terminated: no funding</P>
<P>AA emailed for data/update: 20 December 2011 and 10 May 2012 - no reply received.</P>
<P>A thesis was submitted by Hester F. Shieh in 2012 for partial fulfilment of the requirements for the degree of Doctor of Medicine (University of Arizone College of Medicine - Phoenix) entitled: 'The CLASE Study: Endovascilar Management of the Superficial Femoral Artery'. It stated that the study is a retrospective review of patients that underwent endovascular management of the femoropopliteal segment and evaluated patency. (http://arizona.openrepository.com/arizona/bitstream/10150/221411/1/Shieh,%20Hester.pdf (accessed 11 July 2013)</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-08-07 11:13:27 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-08-07 11:13:02 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-08 13:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Banerjee-2012">
<DESCRIPTION>
<P>Randomisation after stenting, method not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-24 11:47:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-2011">
<DESCRIPTION>
<P>Patients were randomised according to the operator&#8217;s preference to receive cryoplasty</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-13 12:34:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fossaceca-2011">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 11:13:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahnke-2010">
<DESCRIPTION>
<P>The patients were randomly assigned by opening a sealed envelope containing the treatment modality</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 12:31:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shammas-2012">
<DESCRIPTION>
<P>Randomisation by envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-29 13:09:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiliopoulos-2010">
<DESCRIPTION>
<P>Pooled 1:1 envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 13:36:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>Generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-08-07 11:13:05 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-07-08 13:52:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Banerjee-2012">
<DESCRIPTION>
<P>Allocation after stenting, concealment not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-24 11:47:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-2011">
<DESCRIPTION>
<P>Patients were randomised according to the operator&#8217;s preference to receive cryoplasty</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-08 14:55:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fossaceca-2011">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 11:13:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahnke-2010">
<DESCRIPTION>
<P>Sealed envelope containing the treatment modality</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 12:31:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shammas-2012">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-29 13:09:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiliopoulos-2010">
<DESCRIPTION>
<P>Sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-04 12:38:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>Generated random numbers allocated to patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-08-07 11:13:09 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-08-07 05:39:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Banerjee-2012">
<DESCRIPTION>
<P>No information provided on blinding participants. Personnel not blinded to treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-08 15:02:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-2011">
<DESCRIPTION>
<P>Study personnel not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-03-13 12:34:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fossaceca-2011">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-08-07 11:13:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahnke-2010">
<DESCRIPTION>
<P>Treatment assigned by opening sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-21 12:32:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shammas-2012">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-08 14:04:07 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spiliopoulos-2010">
<DESCRIPTION>
<P>Patients randomised only after lesions were successfully crossed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-12 13:37:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-08-07 11:13:12 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-03-13 12:32:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Banerjee-2012">
<DESCRIPTION>
<P>No information provided on blinding outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-02 11:55:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diaz-2011">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-03-13 13:02:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fossaceca-2011">
<DESCRIPTION>
<P>Independent assessors for study outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-07 11:13:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jahnke-2010">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-21 12:32:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shammas-2012">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-08 14:06:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spiliopoulos-2010">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-03-12 13:37:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-08-07 11:13:22 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-07 05:49:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Banerjee-2012">
<DESCRIPTION>
<P>All patients accounted for (9 deaths/90 participants)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-13 12:33:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-2011">
<DESCRIPTION>
<P>48 out of 155 patients were not accounted for at the 36 month follow-up date when the study was published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-12 12:52:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fossaceca-2011">
<DESCRIPTION>
<P>Only one patient excluded at follow-up due to technical failure of the procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-07 11:13:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jahnke-2010">
<DESCRIPTION>
<P>Only 29 patients (40 patients recruited) reached 9 months follow-up, no explanation given about the missing patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-13 13:07:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shammas-2012">
<DESCRIPTION>
<P>All patients accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-13 13:07:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiliopoulos-2010">
<DESCRIPTION>
<P>All patients accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-12 13:37:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>All outcome data presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-08-07 11:13:25 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 05:39:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Banerjee-2012">
<DESCRIPTION>
<P>Expected outcomes presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-27 13:34:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-2011">
<DESCRIPTION>
<P>Outcomes were not reported at all defined time points</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-08 14:59:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fossaceca-2011">
<DESCRIPTION>
<P>Expected outcomes presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 11:13:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahnke-2010">
<DESCRIPTION>
<P>All expected outcomes presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-21 12:33:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shammas-2012">
<DESCRIPTION>
<P>All outcomes presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-13 13:07:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Spiliopoulos-2010">
<DESCRIPTION>
<P>One secondary outcome (30 day complications) not presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 13:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>All outcomes presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-08-07 11:13:27 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 13:00:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Banerjee-2012">
<DESCRIPTION>
<P>Study design required to randomise the patients after stenting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 05:43:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diaz-2011">
<DESCRIPTION>
<P>Operator selection of patient</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-08 15:00:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fossaceca-2011">
<DESCRIPTION>
<P>Post-procedural angiograms and follow-ups evaluated by independent radiologists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-07 11:13:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jahnke-2010">
<DESCRIPTION>
<P>Not evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-13 12:35:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shammas-2012">
<DESCRIPTION>
<P>No evidence for other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-13 13:07:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spiliopoulos-2010">
<DESCRIPTION>
<P>No evidence of other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 13:38:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2011">
<DESCRIPTION>
<P>Study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-08-12 15:18:13 +0100" MODIFIED_BY="Heather  Maxwell"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-07-12 08:06:26 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-07-12 08:06:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Cryoplasty versus angioplasty</NAME>
<DICH_OUTCOME CHI2="2.843347285005451" CI_END="1.00610707812905" CI_START="0.5800240846806176" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7639151373565606" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="255" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.002644204344017178" LOG_CI_START="-0.236553972597886" LOG_EFFECT_SIZE="-0.11695488412693442" METHOD="MH" MODIFIED="2013-06-10 11:15:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8282360318929047" P_Q="0.7993183604660059" P_Z="0.05528478411163723" Q="2.3471451643206946" RANDOM="NO" SCALE="8.208884962475576" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="464" TOTAL_2="414" WEIGHT="600.0" Z="1.9166313358694356">
<NAME>Patency per patient (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Angioplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Cryoplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3701957205334736" CI_START="0.29616636146604214" DF="0" EFFECT_SIZE="0.8378378378378378" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="37" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.37478420965487397" LOG_CI_START="-0.5284642701203187" LOG_EFFECT_SIZE="-0.07684003023272232" MODIFIED="2013-01-24 14:56:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7387786017822574" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.0" Z="0.3334712323337385">
<NAME>3 months</NAME>
<DICH_DATA CI_END="2.3701957205334736" CI_START="0.29616636146604214" EFFECT_SIZE="0.8378378378378378" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="37" LOG_CI_END="0.37478420965487397" LOG_CI_START="-0.5284642701203187" LOG_EFFECT_SIZE="-0.07684003023272232" MODIFIED="2012-05-29 10:51:25 +0100" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.5305726281720329" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" VAR="0.2815073137653783" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5068267937553033" CI_END="1.071464131365118" CI_START="0.3628783084919289" DF="1" EFFECT_SIZE="0.6235471847418991" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="82" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.029977637056859203" LOG_CI_START="-0.44023899152337576" LOG_EFFECT_SIZE="-0.20513067723325826" MODIFIED="2013-01-24 14:56:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4765158058881792" P_Z="0.08725523814485156" STUDIES="2" TAU2="0.0" TOTAL_1="126" TOTAL_2="115" WEIGHT="100.0" Z="1.7100575141948364">
<NAME>6 months</NAME>
<DICH_DATA CI_END="1.0593304569243212" CI_START="0.27581957457939255" EFFECT_SIZE="0.5405405405405406" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="49" LOG_CI_END="0.02503145890979364" LOG_CI_START="-0.5593749157158212" LOG_EFFECT_SIZE="-0.2671717284030138" MODIFIED="2013-01-22 12:14:57 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.34328319731329593" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.11784335355763927" WEIGHT="70.10291664605936"/>
<DICH_DATA CI_END="2.0567127889363723" CI_START="0.3254812685584051" EFFECT_SIZE="0.8181818181818182" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="33" LOG_CI_END="0.31317364857903873" LOG_CI_START="-0.4874740000168391" LOG_EFFECT_SIZE="-0.08715017571890014" MODIFIED="2012-05-29 10:51:25 +0100" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.4703043920549979" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" VAR="0.2211862211862212" WEIGHT="29.89708335394064"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.173833769696914" CI_START="0.576731473609728" DF="0" EFFECT_SIZE="1.3529411764705883" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.5015841767370768" LOG_CI_START="-0.23902634745843895" LOG_EFFECT_SIZE="0.13127891463931898" MODIFIED="2013-01-24 14:56:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4871572134044817" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.0" Z="0.6948373975702443">
<NAME>9 months</NAME>
<DICH_DATA CI_END="3.1738337696969148" CI_START="0.576731473609728" EFFECT_SIZE="1.3529411764705883" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.5015841767370769" LOG_CI_START="-0.23902634745843895" LOG_EFFECT_SIZE="0.13127891463931898" MODIFIED="2012-05-29 10:51:25 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.43503828799366656" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" VAR="0.18925831202046037" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3568936080506733" CI_START="0.3772326937089638" DF="0" EFFECT_SIZE="0.7154471544715447" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="41" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.13254579662958751" LOG_CI_START="-0.42339067520804613" LOG_EFFECT_SIZE="-0.1454224392892293" MODIFIED="2013-01-24 14:56:52 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.3051844891640384" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="69" WEIGHT="100.0" Z="1.0253788265005055">
<NAME>12 months</NAME>
<DICH_DATA CI_END="1.3568936080506733" CI_START="0.3772326937089638" EFFECT_SIZE="0.7154471544715447" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="41" LOG_CI_END="0.13254579662958751" LOG_CI_START="-0.42339067520804613" LOG_EFFECT_SIZE="-0.1454224392892293" MODIFIED="2013-01-22 12:15:37 +0000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.32655983548734413" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.10664132615352127" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4035079428463222" CI_START="0.393626207182528" DF="0" EFFECT_SIZE="0.7432748538011696" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="38" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.14721487477207346" LOG_CI_START="-0.40491599444836474" LOG_EFFECT_SIZE="-0.12885055983814564" MODIFIED="2013-01-24 14:56:52 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.3603008352223458" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="69" WEIGHT="100.00000000000001" Z="0.9147920203308213">
<NAME>24 months</NAME>
<DICH_DATA CI_END="1.4035079428463222" CI_START="0.393626207182528" EFFECT_SIZE="0.7432748538011696" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="38" LOG_CI_END="0.14721487477207346" LOG_CI_START="-0.40491599444836474" LOG_EFFECT_SIZE="-0.12885055983814564" MODIFIED="2013-01-22 12:16:40 +0000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.3243244056719668" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.10518632011447449" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1692411917827633E-31" CI_END="1.4688064391851203" CI_START="0.41136276164459307" DF="0" EFFECT_SIZE="0.777310924369748" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="34" I2="100.0" ID="CMP-001.01.06" LOG_CI_END="0.16696456778992583" LOG_CI_START="-0.38577502509692196" LOG_EFFECT_SIZE="-0.10940522865349808" MODIFIED="2013-01-24 14:56:52 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.43781875899779077" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="69" WEIGHT="100.00000000000001" Z="0.7758818461377063">
<NAME>36 months</NAME>
<DICH_DATA CI_END="1.46880643918512" CI_START="0.411362761644593" EFFECT_SIZE="0.7773109243697479" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="34" LOG_CI_END="0.16696456778992574" LOG_CI_START="-0.385775025096922" LOG_EFFECT_SIZE="-0.10940522865349815" MODIFIED="2013-01-22 12:17:32 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.32468197296684653" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.10541838356964407" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8488935809622318" CI_END="3.765394634175395" CI_START="1.424309657218631" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="2.3158341781516287" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="206" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5758104993848614" LOG_CI_START="0.15360441893668977" LOG_EFFECT_SIZE="0.3647074591607756" METHOD="MH" MODIFIED="2013-06-10 11:15:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8696334115010861" P_Q="0.8708815484384074" P_Z="7.089662830597283E-4" Q="1.839469746414948" RANDOM="NO" SCALE="740.42" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="270" TOTAL_2="270" WEIGHT="600.0" Z="3.3860880643379576">
<NAME>Patency per lesion (adjunctive cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Angioplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Cryoplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="77.32427880170043" CI_START="0.12168285832770595" DF="0" EFFECT_SIZE="3.067415730337079" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="44" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.888315878058954" LOG_CI_START="-0.9147705972672676" LOG_EFFECT_SIZE="0.4867726403958433" MODIFIED="2013-02-27 11:51:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49604943690233705" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.6807188092363703">
<NAME>2 months</NAME>
<DICH_DATA CI_END="77.32427880170043" CI_START="0.12168285832770595" EFFECT_SIZE="3.067415730337079" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="44" LOG_CI_END="1.888315878058954" LOG_CI_START="-0.9147705972672676" LOG_EFFECT_SIZE="0.4867726403958433" MODIFIED="2013-01-23 13:43:24 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="1.6465468711084565" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="2.711116598757048" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="31.42049282617206" CI_START="0.314366521080807" DF="0" EFFECT_SIZE="3.142857142857143" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="42" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="1.4972129926074722" LOG_CI_START="-0.5025637109915734" LOG_EFFECT_SIZE="0.4973246408079494" MODIFIED="2013-02-27 11:51:47 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.32963606044972094" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.9748472245462607">
<NAME>4 months</NAME>
<DICH_DATA CI_END="31.420492826172048" CI_START="0.31436652108080715" EFFECT_SIZE="3.142857142857143" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="42" LOG_CI_END="1.497212992607472" LOG_CI_START="-0.5025637109915732" LOG_EFFECT_SIZE="0.4973246408079494" MODIFIED="2013-01-23 13:44:17 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="1.1746787347484118" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="1.3798701298701297" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="26.486253012219652" CI_START="1.090778109937675" DF="0" EFFECT_SIZE="5.374999999999999" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="36" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.4230205233701854" LOG_CI_START="0.03773641380510051" LOG_EFFECT_SIZE="0.7303784685876429" MODIFIED="2013-02-27 11:51:47 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.03875805372864946" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="2.0667464293151085">
<NAME>6 months</NAME>
<DICH_DATA CI_END="26.486253012219652" CI_START="1.090778109937675" EFFECT_SIZE="5.375" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="36" LOG_CI_END="1.4230205233701854" LOG_CI_START="0.03773641380510051" LOG_EFFECT_SIZE="0.730378468587643" MODIFIED="2013-01-23 13:45:21 +0000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.8137227432254658" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="0.6621447028423773" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.7321886753838776" CI_START="0.9018016351338995" DF="0" EFFECT_SIZE="2.640625" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.888302442831729" LOG_CI_START="-0.044888981572156185" LOG_EFFECT_SIZE="0.42170673062978636" MODIFIED="2013-02-27 11:51:47 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0764933683002553" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="1.7714050567931352">
<NAME>8 months</NAME>
<DICH_DATA CI_END="7.7321886753838776" CI_START="0.9018016351338995" EFFECT_SIZE="2.640625" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.888302442831729" LOG_CI_START="-0.044888981572156185" LOG_EFFECT_SIZE="0.42170673062978636" MODIFIED="2013-01-23 13:50:48 +0000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.5481612620668932" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="0.3004807692307692" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.252094715705597" CI_START="0.6839329122640718" DF="0" EFFECT_SIZE="1.7053291536050157" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.6286029298988014" LOG_CI_START="-0.16498649661680387" LOG_EFFECT_SIZE="0.2318082166409988" MODIFIED="2013-02-27 11:51:47 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.2522031120150616" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="1.1450146404587511">
<NAME>10 months</NAME>
<DICH_DATA CI_END="4.252094715705596" CI_START="0.6839329122640719" EFFECT_SIZE="1.7053291536050157" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" LOG_CI_END="0.6286029298988013" LOG_CI_START="-0.16498649661680378" LOG_EFFECT_SIZE="0.2318082166409988" MODIFIED="2013-01-23 13:53:17 +0000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.46615835746628304" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="0.2173036142356629" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.484474111343112" CI_START="0.8160901944911318" DF="0" EFFECT_SIZE="1.9130434782608696" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" I2="0.0" ID="CMP-001.02.06" LOG_CI_END="0.6517115211966561" LOG_CI_START="-0.08826184025946701" LOG_EFFECT_SIZE="0.2817248404685946" MODIFIED="2013-02-27 11:51:47 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.13559260240962404" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="1.4924065368574184">
<NAME>12 months</NAME>
<DICH_DATA CI_END="4.484474111343112" CI_START="0.8160901944911318" EFFECT_SIZE="1.9130434782608696" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="23" LOG_CI_END="0.6517115211966561" LOG_CI_START="-0.08826184025946701" LOG_EFFECT_SIZE="0.2817248404685946" MODIFIED="2013-01-23 13:46:14 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.4346640154465408" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="0.1889328063241107" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15251089682672433" CI_END="2.8779962888778976" CI_START="0.45254317824341567" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.141235114926613" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.45909022958637863" LOG_CI_START="-0.3443399773908556" LOG_EFFECT_SIZE="0.05737512609776156" METHOD="MH" MODIFIED="2013-06-10 11:16:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.6961474789537563" P_Q="0.6961577385163467" P_Z="0.7795291635433561" Q="0.15250005805969508" RANDOM="NO" SCALE="236.11" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="66" WEIGHT="200.0" Z="0.2799326681607908">
<NAME>Restenosis per patient (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.976735855722432" CI_START="0.3548608985453512" DF="0" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.4737402987072645" LOG_CI_START="-0.44994185210784904" LOG_EFFECT_SIZE="0.01189922329970769" MODIFIED="2012-05-29 10:55:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9597255457530156" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.0" Z="0.050497996720725066">
<NAME>Within 24 hours (immediate)</NAME>
<DICH_DATA CI_END="2.976735855722432" CI_START="0.3548608985453512" EFFECT_SIZE="1.0277777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.4737402987072645" LOG_CI_START="-0.44994185210784904" LOG_EFFECT_SIZE="0.01189922329970769" MODIFIED="2012-05-29 10:55:19 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.5425754676891853" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" VAR="0.29438813813813813" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.704440944201158" CI_START="0.2356490509527693" DF="0" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="1.0295639905292364" LOG_CI_START="-0.6277343049678096" LOG_EFFECT_SIZE="0.20091484278071337" MODIFIED="2013-02-27 11:51:39 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6346342964231444" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.4752142168729183">
<NAME>6 months</NAME>
<DICH_DATA CI_END="10.704440944201158" CI_START="0.2356490509527693" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0295639905292364" LOG_CI_START="-0.6277343049678096" LOG_EFFECT_SIZE="0.20091484278071337" MODIFIED="2012-12-12 13:40:51 +0000" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.973505222533836" STUDY_ID="STD-Shammas-2012" TOTAL_1="20" TOTAL_2="20" VAR="0.9477124183006536" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.039643001033854" CI_END="0.2775548567593036" CI_START="0.0770234203583243" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.14621294198758988" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="47" I2="88.93761623234866" I2_Q="88.87535888594022" ID="CMP-001.04" LOG_CI_END="-0.5566511688173988" LOG_CI_START="-1.1133771996867483" LOG_EFFECT_SIZE="-0.8350141842520736" METHOD="MH" MODIFIED="2013-06-10 11:16:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0026418791808059394" P_Q="0.0027160461083343135" P_Z="4.118437080361044E-9" Q="8.989054026526373" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="98" WEIGHT="200.0" Z="5.8793648472249265">
<NAME>Restenosis per lesion (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.17691009465208635" CI_START="0.040280295515293926" DF="0" EFFECT_SIZE="0.08441558441558442" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="44" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.7522473851421907" LOG_CI_START="-1.394907351917062" LOG_EFFECT_SIZE="-1.0735773685296264" MODIFIED="2012-05-29 10:55:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="5.818621250153236E-11" STUDIES="1" TAU2="0.0" TOTAL_1="118" TOTAL_2="74" WEIGHT="99.99999999999999" Z="6.548324419505846">
<NAME>Within 24 hours (immediate)</NAME>
<DICH_DATA CI_END="0.17691009465208635" CI_START="0.040280295515293926" EFFECT_SIZE="0.08441558441558442" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="44" LOG_CI_END="-0.7522473851421907" LOG_CI_START="-1.394907351917062" LOG_EFFECT_SIZE="-1.0735773685296264" MODIFIED="2012-05-29 10:55:19 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.3775016457017009" STUDY_ID="STD-Diaz-2011" TOTAL_1="118" TOTAL_2="74" VAR="0.1425074925074925" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.379655435524429" CI_START="0.25390630060111474" DF="0" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.8047972231582448" LOG_CI_START="-0.595326522118219" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2013-02-27 11:51:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7693481324985998" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="0.29322767451082754">
<NAME>6 months</NAME>
<DICH_DATA CI_END="6.379655435524429" CI_START="0.25390630060111474" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8047972231582448" LOG_CI_START="-0.595326522118219" LOG_EFFECT_SIZE="0.10473535052001298" MODIFIED="2012-12-12 13:41:35 +0000" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.8224396186997112" STUDY_ID="STD-Shammas-2012" TOTAL_1="26" TOTAL_2="24" VAR="0.6764069264069263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.83005874975459" CI_END="1.5241831369621173" CI_START="0.04808890109430505" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.27073287964888726" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="64" I2="88.67504703716958" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.18303715243247623" LOG_CI_START="-1.3179551471127666" LOG_EFFECT_SIZE="-0.5674589973401452" METHOD="MH" MODIFIED="2013-06-10 11:21:35 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.002963111256421458" P_Q="1.0" P_Z="0.13835309308016244" Q="0.0" RANDOM="YES" SCALE="61.29850202948026" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.379345364901342" TOTALS="YES" TOTAL_1="126" TOTAL_2="115" WEIGHT="100.0" Z="1.4819519031867907">
<NAME>Need for re-intervention per patient - no time interval (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.23919537237215766" CI_START="0.05460483771180284" EFFECT_SIZE="0.11428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="46" LOG_CI_END="-0.6212472267433137" LOG_CI_START="-1.2627688793013128" LOG_EFFECT_SIZE="-0.9420080530223133" MODIFIED="2013-01-22 15:05:32 +0000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.3768329942959641" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.14200310559006213" WEIGHT="51.09794449833077"/>
<DICH_DATA CI_END="1.637845821605058" CI_START="0.27135914661912264" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" LOG_CI_END="0.2142730170961743" LOG_CI_START="-0.5664555352075369" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2012-05-29 10:57:45 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.4586038162918624" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" VAR="0.2103174603174603" WEIGHT="48.90205550166923"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="33.84189037602614" CI_END="5.685595443207468" CI_START="0.06149235663115361" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5912872928231889" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="68" I2="94.0901646516271" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.7547759543636935" LOG_CI_START="-1.211178862748263" LOG_EFFECT_SIZE="-0.22820145419228466" METHOD="MH" MODIFIED="2013-06-10 11:21:39 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="4.4805644416889834E-8" P_Q="1.0" P_Z="0.6491005231530504" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.7538654274981673" TOTALS="YES" TOTAL_1="175" TOTAL_2="132" WEIGHT="100.0" Z="0.4550121168029613">
<NAME>Need for re-intervention per lesion - no time interval (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.17691009465208635" CI_START="0.040280295515293926" EFFECT_SIZE="0.08441558441558442" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="44" LOG_CI_END="-0.7522473851421907" LOG_CI_START="-1.394907351917062" LOG_EFFECT_SIZE="-1.0735773685296264" MODIFIED="2013-01-22 15:06:55 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.3775016457017009" STUDY_ID="STD-Diaz-2011" TOTAL_1="118" TOTAL_2="74" VAR="0.1425074925074925" WEIGHT="34.22644183604371"/>
<DICH_DATA CI_END="2.71573934581051" CI_START="0.281921385858001" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.4338880844197838" LOG_CI_START="-0.5498719783751573" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2012-12-12 13:23:10 +0000" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.5778655305765966" STUDY_ID="STD-Shammas-2012" TOTAL_1="26" TOTAL_2="24" VAR="0.33392857142857146" WEIGHT="32.623703922732716"/>
<DICH_DATA CI_END="8.29158955789422" CI_START="1.0854372297566661" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.9186377959358785" LOG_CI_START="0.035604713503446524" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-01-30 14:22:06 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.5186980037050645" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="31" TOTAL_2="34" VAR="0.26904761904761904" WEIGHT="33.14985424122358"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.627540209530746" CI_START="0.25717391761978414" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.6653502011043484" LOG_CI_START="-0.5897730793255489" LOG_EFFECT_SIZE="0.037788560889399754" METHOD="MH" MODIFIED="2013-06-10 11:21:15 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.9060525765784058" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="92" TOTAL_2="98" WEIGHT="200.0" Z="0.11801903370871165">
<NAME>Limb loss (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-12-12 12:47:47 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>6 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-12 12:36:04 +0000" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.0" STUDY_ID="STD-Shammas-2012" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-10 11:21:15 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-01-30 14:11:22 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.0" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.41966367175445" CI_START="0.14134562745308746" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.9252947437064848" LOG_CI_START="-0.8497176219276854" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2013-01-30 14:11:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.9334920957040376" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.08345205904451375">
<NAME>24 months</NAME>
<DICH_DATA CI_END="8.41966367175445" CI_START="0.14134562745308746" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9252947437064848" LOG_CI_START="-0.8497176219276854" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2013-01-30 14:11:08 +0000" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="1.0426510500264277" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="1.0871212121212122" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.41966367175445" CI_START="0.14134562745308746" DF="0" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.9252947437064848" LOG_CI_START="-0.8497176219276854" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2013-01-30 14:10:35 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9334920957040376" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="100.0" Z="0.08345205904451375">
<NAME>3 years</NAME>
<DICH_DATA CI_END="8.41966367175445" CI_START="0.14134562745308746" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9252947437064848" LOG_CI_START="-0.8497176219276854" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2013-01-30 14:10:35 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.0426510500264277" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="1.0871212121212122" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-07-12 08:06:26 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Limb loss (adjunctive cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-18 14:44:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-10 11:20:42 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.0" STUDY_ID="STD-Banerjee-2012" TOTAL_1="37" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.682553534632277" CI_END="19.54965921212921" CI_START="0.13570764788568315" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.628814989077867" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="57" I2="94.91935841434163" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.2911391912161947" LOG_CI_START="-0.8673956767252449" LOG_EFFECT_SIZE="0.21187175724547483" METHOD="MH" MODIFIED="2013-06-10 15:22:18 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="9.143442230352683E-6" P_Q="1.0" P_Z="0.7004138130682478" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.0522989168170795" TOTALS="YES" TOTAL_1="136" TOTAL_2="130" WEIGHT="100.00000000000001" Z="0.3847619232005938">
<NAME>Immediate success of procedure per patient - within 24 hours (primary cryoplasty trials))</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Angioplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Cryoplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="11.551370297864084" CI_START="2.822337089201335" EFFECT_SIZE="5.709803921568628" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="17" LOG_CI_END="1.0626335060897636" LOG_CI_START="0.45060888299636287" LOG_EFFECT_SIZE="0.7566211945430632" MODIFIED="2013-01-22 11:56:25 +0000" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.3595062931758081" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.1292447748330101" WEIGHT="50.530715665696334"/>
<DICH_DATA CI_END="1.0807493520258125" CI_START="0.18929666544535098" EFFECT_SIZE="0.4523076923076923" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.033724983820125225" LOG_CI_START="-0.7228570362815218" LOG_EFFECT_SIZE="-0.34456602623069826" MODIFIED="2013-01-30 13:59:24 +0000" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.4444200237491078" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" VAR="0.1975091575091575" WEIGHT="49.46928433430368"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-29 11:02:02 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Wang-2011" TOTAL_1="10" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-07-12 08:06:14 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Immediate success of procedure per patient - within 24 hours (adjunctive cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Angioplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Cryoplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-10 11:25:24 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Banerjee-2012" TOTAL_1="37" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.50593933530996" CI_END="17.358234527799272" CI_START="0.1893823675728327" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8131032931852276" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="62" I2="90.24672819276256" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="1.2395055518413394" LOG_CI_START="-0.7226604583965964" LOG_EFFECT_SIZE="0.25842254672237147" METHOD="MH" MODIFIED="2013-06-10 15:22:40 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="3.525297762319024E-5" P_Q="1.0" P_Z="0.6056692922929803" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.225498763194539" TOTALS="YES" TOTAL_1="175" TOTAL_2="132" WEIGHT="100.0" Z="0.5162650680179182">
<NAME>Immediate success of procedure per lesion - within 24 hours (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Angioplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Cryoplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.229401670210915" CI_START="5.32599926904367" EFFECT_SIZE="10.633333333333333" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="16" LOG_CI_END="1.326937754176006" LOG_CI_START="0.7264011024990317" LOG_EFFECT_SIZE="1.0266694283375186" MODIFIED="2012-05-29 11:02:47 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.35275820189942364" STUDY_ID="STD-Diaz-2011" TOTAL_1="118" TOTAL_2="74" VAR="0.12443834900731451" WEIGHT="39.656104154025684"/>
<DICH_DATA CI_END="8.932301691082442" CI_START="0.013475419675164753" EFFECT_SIZE="0.3469387755102041" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="24" LOG_CI_END="0.9509633830693123" LOG_CI_START="-1.870457700369792" LOG_EFFECT_SIZE="-0.45974715865023974" MODIFIED="2012-12-12 13:25:10 +0000" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.6573167106717377" STUDY_ID="STD-Shammas-2012" TOTAL_1="26" TOTAL_2="24" VAR="2.7466986794717885" WEIGHT="22.24398243799572"/>
<DICH_DATA CI_END="2.056709162825103" CI_START="0.2773336408640364" EFFECT_SIZE="0.7552447552447552" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.3131728828904546" LOG_CI_START="-0.556997446846679" LOG_EFFECT_SIZE="-0.12191228197811213" MODIFIED="2012-05-29 11:02:47 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.5111423591001936" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="31" TOTAL_2="34" VAR="0.26126651126651124" WEIGHT="38.09991340797859"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-07-12 08:05:56 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Immediate success of procedure per lesion - within 24 hours (adjunctive cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Angioplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Cryoplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="45" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-06-10 11:30:06 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.0" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4208138254704537" CI_END="2.649709365422189" CI_START="0.8803284122420568" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.5272898999747964" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.4231982407611686" LOG_CI_START="-0.05535528123946297" LOG_EFFECT_SIZE="0.1839214797608528" METHOD="MH" MODIFIED="2013-06-10 15:23:17 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.8772225347977175" P_Q="0.7094242003050664" P_Z="0.13192918050707328" Q="1.3834273766038732" RANDOM="NO" SCALE="176.54" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="532" TOTAL_2="476" WEIGHT="400.0" Z="1.5065377632477577">
<NAME>Death from all causes (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-05-29 11:05:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>30 days</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-29 11:05:59 +0100" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.0" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-05-29 11:07:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>3 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-29 11:07:16 +0100" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.0" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="30.381777141246022" CI_START="0.36215703804405064" DF="0" EFFECT_SIZE="3.317073170731707" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="1.4826131737421557" LOG_CI_START="-0.44110307044119157" LOG_EFFECT_SIZE="0.520755051650482" MODIFIED="2013-01-21 12:10:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.28862865103379154" STUDIES="3" TAU2="0.0" TOTAL_1="130" TOTAL_2="115" WEIGHT="100.0" Z="1.0611348207807332">
<NAME>6 months</NAME>
<DICH_DATA CI_END="30.381777141246022" CI_START="0.3621570380440505" EFFECT_SIZE="3.317073170731707" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.4826131737421557" LOG_CI_START="-0.4411030704411917" LOG_EFFECT_SIZE="0.520755051650482" MODIFIED="2013-01-21 12:10:03 +0000" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="1.1300004443822846" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="1.2769010043041606" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-06-21 12:35:47 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.0" STUDY_ID="STD-Shammas-2012" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-29 11:07:35 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.43066032002673166" CI_END="9.132203207900005" CI_START="0.5990565986624733" DF="1" EFFECT_SIZE="2.3389541662929405" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-001.13.04" LOG_CI_END="0.9605755667568486" LOG_CI_START="-0.2225321436781666" LOG_EFFECT_SIZE="0.369021711539341" MODIFIED="2013-06-10 12:05:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5116651375686749" P_Z="0.2214581462381321" STUDIES="3" TAU2="0.0" TOTAL_1="134" TOTAL_2="119" WEIGHT="100.0" Z="1.2226600465049788">
<NAME>12 months</NAME>
<DICH_DATA CI_END="14.77349929460051" CI_START="0.5964144207578095" EFFECT_SIZE="2.9683544303797467" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1694833757681546" LOG_CI_START="-0.2244518642468334" LOG_EFFECT_SIZE="0.4725157557606606" MODIFIED="2013-01-21 12:10:56 +0000" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.8188044600755253" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.6704407438395725" WEIGHT="68.02403803031662"/>
<DICH_DATA CI_END="16.969595377382827" CI_START="0.05892892421776925" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.229671487134124" LOG_CI_START="-1.2296714871341243" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-29 11:08:02 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="1.4446302370292305" STUDY_ID="STD-Fossaceca-2011" TOTAL_1="24" TOTAL_2="24" VAR="2.086956521739131" WEIGHT="31.975961969683382"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-05-29 11:08:02 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.0" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6624070412139144" CI_END="4.006015984575828" CI_START="0.5742992192644889" DF="1" EFFECT_SIZE="1.5167899829254412" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-001.13.05" LOG_CI_END="0.6027126778580136" LOG_CI_START="-0.24086177412342133" LOG_EFFECT_SIZE="0.18092545186729614" MODIFIED="2013-01-21 12:11:35 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4157117561209981" P_Z="0.400501616247938" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="95" WEIGHT="100.0" Z="0.8407257206844372">
<NAME>24 months</NAME>
<DICH_DATA CI_END="3.6332306785559374" CI_START="0.41456171665546193" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5602929726613696" LOG_CI_START="-0.3824108059878074" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2013-01-21 12:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.5537488660374905" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.30663780663780665" WEIGHT="87.64940239043824"/>
<DICH_DATA CI_END="36.94075470450097" CI_START="0.3452853668759022" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5675057638885237" LOG_CI_START="-0.46182182657296217" LOG_EFFECT_SIZE="0.5528419686577808" MODIFIED="2012-05-29 11:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="1.1920370719706586" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="1.420952380952381" WEIGHT="12.350597609561753"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.3398873888601477E-4" CI_END="2.587826756288224" CI_START="0.4784000611032463" DF="1" EFFECT_SIZE="1.1126618885954986" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" ID="CMP-001.13.06" LOG_CI_END="0.41293519884888574" LOG_CI_START="-0.3202087735497438" LOG_EFFECT_SIZE="0.046363212649570947" MODIFIED="2013-01-21 12:11:51 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.983379354977631" P_Z="0.8042180456370727" STUDIES="2" TAU2="0.0" TOTAL_1="110" TOTAL_2="95" WEIGHT="100.0" Z="0.24789190233244496">
<NAME>3 years</NAME>
<DICH_DATA CI_END="2.954207047002318" CI_START="0.42335199413782426" EFFECT_SIZE="1.1183333333333334" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.4704409297773886" LOG_CI_START="-0.37329839020669175" LOG_EFFECT_SIZE="0.04857126978534847" MODIFIED="2013-01-21 12:11:51 +0000" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.4956166531356418" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="0.24563586686537506" WEIGHT="75.44322897019993"/>
<DICH_DATA CI_END="6.032209507070352" CI_START="0.1988569004201169" EFFECT_SIZE="1.0952380952380953" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7804764167782443" LOG_CI_START="-0.701459334210897" LOG_EFFECT_SIZE="0.039508541283673655" MODIFIED="2012-05-29 11:08:49 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.8704963958312977" STUDY_ID="STD-Spiliopoulos-2010" TOTAL_1="24" TOTAL_2="26" VAR="0.7577639751552794" WEIGHT="24.556771029800075"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-07-12 08:05:28 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>Deaths from all causes (adjunctive cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-06-18 14:44:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<DICH_DATA CI_END="9.824173622544475" CI_START="0.24269718752598157" EFFECT_SIZE="1.5441176470588236" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9922960291479368" LOG_CI_START="-0.6149352564205331" LOG_EFFECT_SIZE="0.18868038636370177" MODIFIED="2013-06-10 12:05:34 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.9440956130660942" STUDY_ID="STD-Banerjee-2012" TOTAL_1="37" TOTAL_2="37" VAR="0.8913165266106443" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5130542946968708" CI_END="7.366299685583822" CI_START="0.6953239198283367" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.2631757271609265" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.8672493834230239" LOG_CI_START="-0.15781283019906764" LOG_EFFECT_SIZE="0.3547182766119782" METHOD="MH" MODIFIED="2013-06-10 15:23:26 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.4692935005656834" P_Q="1.0" P_Z="0.17494844817969143" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="150" WEIGHT="100.0" Z="1.3564738560812961">
<NAME>Complications - Immediate post treatment (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="43.41412708516097" CI_START="0.5991137389214087" EFFECT_SIZE="5.1" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6376310732175259" LOG_CI_START="-0.22249072102165343" LOG_EFFECT_SIZE="0.7075701760979364" MODIFIED="2012-05-29 11:09:59 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="1.0926447496874763" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" VAR="1.1938725490196078" WEIGHT="26.334088226850817"/>
<DICH_DATA CI_END="11.252257075363001" CI_START="0.28277745220172584" EFFECT_SIZE="1.7837837837837838" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0512396457413153" LOG_CI_START="-0.5485552227915681" LOG_EFFECT_SIZE="0.2513422114748737" MODIFIED="2012-05-29 11:09:59 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.9397274248885328" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" VAR="0.883087633087633" WEIGHT="43.902905808427164"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-01 13:00:12 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.0" STUDY_ID="STD-Shammas-2012" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.451458959217813" CI_START="0.017017456746805788" EFFECT_SIZE="0.4603174603174603" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.095220241457065" LOG_CI_START="-1.7691053445663165" LOG_EFFECT_SIZE="-0.33694255155462566" MODIFIED="2012-05-29 11:09:59 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="1.6825190278704552" STUDY_ID="STD-Wang-2011" TOTAL_1="10" TOTAL_2="15" VAR="2.8308702791461413" WEIGHT="29.76300596472202"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2013-07-12 08:04:56 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Complications - immediate post treatment (adjunctive cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.484044836858424" CI_START="0.2877148853032382" EFFECT_SIZE="1.3658536585365855" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8118460093123309" LOG_CI_START="-0.541037668739401" LOG_EFFECT_SIZE="0.13540417028646495" MODIFIED="2013-06-10 12:08:12 +0100" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.7946905693697995" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" VAR="0.6315331010452961" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.01170185641426" CI_END="0.05516207154915471" CI_START="-0.02703971914648661" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="0.014061176201334047" ESTIMABLE="YES" I2="14.428763189478193" I2_Q="25.529759121441124" ID="CMP-001.17" MODIFIED="2013-07-11 13:33:55 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.31976656470187914" P_Q="0.24278693507900495" P_Z="0.5025197516613356" Q="6.714091348453764" RANDOM="NO" SCALE="1.0271568559445208" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="246" TOTAL_2="257" UNITS="" WEIGHT="600.0" Z="0.6705303790017747">
<NAME>Ankle brachial index (primary cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.2976105079604966" CI_END="0.029144269399404052" CI_START="-0.1234071798791002" DF="1" EFFECT_SIZE="-0.047131455239848075" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" MODIFIED="2012-05-29 11:14:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5853843960984343" P_Z="0.22586501818950555" STUDIES="2" TAU2="0.0" TOTAL_1="126" TOTAL_2="115" WEIGHT="100.0" Z="1.2110793472754031">
<NAME>Within 24 hours</NAME>
<CONT_DATA CI_END="0.02696880914568743" CI_START="-0.1269688091456873" EFFECT_SIZE="-0.04999999999999993" ESTIMABLE="YES" MEAN_1="0.89" MEAN_2="0.94" MODIFIED="2012-05-29 11:14:24 +0100" MODIFIED_BY="[Empty name]" ORDER="47" SD_1="0.14" SD_2="0.22" SE="0.039270522189595064" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" WEIGHT="98.2071595249051"/>
<CONT_DATA CI_END="0.6796597279383101" CI_START="-0.4596597279383101" EFFECT_SIZE="0.10999999999999999" ESTIMABLE="YES" MEAN_1="0.83" MEAN_2="0.72" MODIFIED="2012-05-29 11:14:24 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="1.762" SD_2="1.827" SE="0.29064805906216307" STUDY_ID="STD-Diaz-2011" TOTAL_1="86" TOTAL_2="69" WEIGHT="1.7928404750949092"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.14907023831649518" CI_START="-0.10907023831649515" DF="0" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.02" MODIFIED="2012-05-29 11:14:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.761352631320968" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="15" WEIGHT="100.0" Z="0.3037050229556402">
<NAME>2 days</NAME>
<CONT_DATA CI_END="0.14907023831649518" CI_START="-0.10907023831649515" EFFECT_SIZE="0.020000000000000018" ESTIMABLE="YES" MEAN_1="0.88" MEAN_2="0.86" MODIFIED="2012-05-29 11:14:32 +0100" MODIFIED_BY="[Empty name]" ORDER="4" SD_1="0.09" SD_2="0.23" SE="0.06585337247754793" STUDY_ID="STD-Wang-2011" TOTAL_1="10" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.12544790274097956" CI_START="-0.12544790274097956" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.03" MODIFIED="2012-05-29 11:18:39 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>30 days</NAME>
<CONT_DATA CI_END="0.12544790274097956" CI_START="-0.12544790274097956" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.84" MEAN_2="0.84" MODIFIED="2012-05-29 11:18:39 +0100" MODIFIED_BY="[Empty name]" ORDER="3" SD_1="0.13" SD_2="0.19" SE="0.06400520812142295" STUDY_ID="STD-Wang-2011" TOTAL_1="10" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2420765488128448" CI_START="0.01792345118715523" DF="0" EFFECT_SIZE="0.13" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.04" MODIFIED="2012-05-29 11:18:56 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.02300182189441906" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.00000000000001" Z="2.2734043891348454">
<NAME>3 months</NAME>
<CONT_DATA CI_END="0.2420765488128448" CI_START="0.01792345118715523" EFFECT_SIZE="0.13" ESTIMABLE="YES" MEAN_1="0.96" MEAN_2="0.83" MODIFIED="2012-05-29 11:18:56 +0100" MODIFIED_BY="[Empty name]" ORDER="48" SD_1="0.19" SD_2="0.33" SE="0.05718296340998625" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.16649569692985378" CI_START="-0.10649569692985394" DF="0" EFFECT_SIZE="0.029999999999999916" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.05" MODIFIED="2012-12-12 13:52:39 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.666632056529505" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.43077489517064166">
<NAME>6 months</NAME>
<CONT_DATA CI_END="0.16649569692985378" CI_START="-0.10649569692985394" EFFECT_SIZE="0.029999999999999916" ESTIMABLE="YES" MEAN_1="0.82" MEAN_2="0.79" MODIFIED="2012-12-12 13:52:39 +0000" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="0.21" SD_2="0.23" SE="0.0696419413859206" STUDY_ID="STD-Shammas-2012" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.09827063126910048" CI_START="-0.05827063126910066" DF="0" EFFECT_SIZE="0.019999999999999907" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.06" MODIFIED="2012-12-12 13:51:54 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.6164997697033421" STUDIES="1" TAU2="0.0" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.00000000000001" Z="0.5008172165627579">
<NAME>9 months</NAME>
<CONT_DATA CI_END="0.09827063126910048" CI_START="-0.05827063126910066" EFFECT_SIZE="0.019999999999999907" ESTIMABLE="YES" MEAN_1="0.94" MEAN_2="0.92" MODIFIED="2012-05-29 11:19:35 +0100" MODIFIED_BY="[Empty name]" ORDER="49" SD_1="0.18" SD_2="0.19" SE="0.03993472935548271" STUDY_ID="STD-Jahnke-2010" TOTAL_1="40" TOTAL_2="46" WEIGHT="100.00000000000001"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2013-07-12 08:04:34 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.34" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="45" TOTAL_2="45" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Ankle brachial index (adjunctive cryoplasty trials)</NAME>
<GROUP_LABEL_1>Cryoplasty</GROUP_LABEL_1>
<GROUP_LABEL_2>Angioplasty</GROUP_LABEL_2>
<GRAPH_LABEL_1>Cryoplasty</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Angioplasty</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.18.01" MODIFIED="2013-06-18 14:44:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>12 months</NAME>
<CONT_DATA CI_END="0.23598983769100867" CI_START="0.004010162308991316" EFFECT_SIZE="0.12" ESTIMABLE="YES" MEAN_1="0.77" MEAN_2="0.65" MODIFIED="2013-06-10 12:19:44 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="0.3" SD_2="0.26" SE="0.05917957605645906" STUDY_ID="STD-Banerjee-2012" TOTAL_1="45" TOTAL_2="45" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-08-07 11:13:28 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-08-07 11:13:28 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-08-07 11:13:28 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAU8AAAInCAIAAACX4EwPAAAbO0lEQVR42u3dsY4cxxHG8QUMGA4u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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-07-12 08:04:05 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-07-12 08:04:05 +0100" MODIFIED_BY="Karen Welch" NO="1">
<TITLE MODIFIED="2012-01-26 09:57:37 +0000" MODIFIED_BY="Karen Welch">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-07-12 08:04:05 +0100" MODIFIED_BY="Karen Welch">
<P>#1 MeSH descriptor: [Arteriosclerosis] this term only 893<BR/>
<BR/>#2 MeSH descriptor: [Arteriolosclerosis] this term only 0<BR/>
<BR/>#3 MeSH descriptor: [Arteriosclerosis Obliterans] this term only 71<BR/>
<BR/>#4 MeSH descriptor: [Atherosclerosis] this term only 379<BR/>
<BR/>#5 MeSH descriptor: [Arterial Occlusive Diseases] this term only 753<BR/>
<BR/>#6 MeSH descriptor: [Intermittent Claudication] this term only 708<BR/>
<BR/>#7 MeSH descriptor: [Ischemia] this term only 747<BR/>
<BR/>#8 MeSH descriptor: [Peripheral Vascular Diseases] explode all trees 2140<BR/>
<BR/>#9 atherosclero* or arteriosclero* or PVD or PAOD or PAD 16742<BR/>
<BR/>#10 (arter* or vascular or vein* or veno* or peripher*) near (occlus* or reocclus* or re-occlus* or steno* or obstruct* or lesio* or block* or harden* or stiffen*) 7851<BR/>
<BR/>#11 peripheral near/3 dis* 3181<BR/>
<BR/>#12 claudic* or IC 3325<BR/>
<BR/>#13 isch* or CLI 16610<BR/>
<BR/>#14 re-vasculari* or revasculari* 4571<BR/>
<BR/>#15 MeSH descriptor: [Popliteal Artery] explode all trees 248<BR/>
<BR/>#16 MeSH descriptor: [Femoral Artery] explode all trees 715<BR/>
<BR/>#17 infrainguinal or inguinal 1686<BR/>
<BR/>#18 femoro* or femora* 5299<BR/>
<BR/>#19 infrapopliteal or poplite* 702<BR/>
<BR/>#20 MeSH descriptor: [Iliac Artery] explode all trees 151<BR/>
<BR/>#21 iliac 981<BR/>
<BR/>#22 ileo* 581<BR/>
<BR/>#23 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22) 48958<BR/>
<BR/>#24 MeSH descriptor: [Cryotherapy] explode all trees 1030<BR/>
<BR/>#25 cryo* 2074<BR/>
<BR/>#26 Polarcath* 2<BR/>
<BR/>#27 MeSH descriptor: [Cold Temperature] explode all trees 1096<BR/>
<BR/>#28 cold 5131<BR/>
<BR/>#29 cool* 1726<BR/>
<BR/>#30 #24 or #25 or #26 or #27 or #28 or #29 8544<BR/>
<BR/>#31 #23 and #30 877 in Trials<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>